{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "ShNLBi1-_2Se"
   },
   "source": [
    "# Initializing the Guide to Pharmacology Database\n",
    "\n",
    "---\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "ugWh9WTCASLv"
   },
   "source": [
    "## Setup and Data Loading\n",
    "\n",
    "First, let's review the setup and data loading process:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "hIdweyPbkPnH",
    "outputId": "b9ab718f-4a64-4f81-8605-bd48303b0671"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m A new release of pip is available: \u001b[0m\u001b[31;49m24.0\u001b[0m\u001b[39;49m -> \u001b[0m\u001b[32;49m24.3.1\u001b[0m\n",
      "\u001b[1m[\u001b[0m\u001b[34;49mnotice\u001b[0m\u001b[1;39;49m]\u001b[0m\u001b[39;49m To update, run: \u001b[0m\u001b[32;49mpip install --upgrade pip\u001b[0m\n"
     ]
    }
   ],
   "source": [
    "!pip install -q rdflib-neo4j openpyxl"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "id": "dkxR9IazkLaY",
    "pycharm": {
     "is_executing": true,
     "name": "#%%\n"
    }
   },
   "outputs": [],
   "source": [
    "from rdflib_neo4j import Neo4jStoreConfig\n",
    "from rdflib_neo4j import HANDLE_VOCAB_URI_STRATEGY\n",
    "# from google.colab import userdata"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {
    "id": "XyQu2-_IkOh9"
   },
   "outputs": [],
   "source": [
    "import os\n",
    "\n",
    "# NEO_DB_URI = 'bolt://172.18.176.1:7687'\n",
    "NEO_DB_URI = os.getenv('NEO4J_LCL_URI')\n",
    "NEO_DB_USERNAME = os.getenv('NEO4J_USERNAME')\n",
    "NEO_DB_PWD = os.getenv('NEO4J_LCL_PASSWORD')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {
    "id": "y9QD9_o3rEu1"
   },
   "outputs": [],
   "source": [
    "auth_data = {'uri': NEO_DB_URI,\n",
    "             'database': \"neo4j\",\n",
    "             'user': NEO_DB_USERNAME,\n",
    "             'pwd': NEO_DB_PWD}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "Prt_xi-5-ctl"
   },
   "source": [
    "## Define namespaces and configuration\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "id": "091uEorDkLaZ",
    "pycharm": {
     "name": "#%%\n"
    }
   },
   "outputs": [],
   "source": [
    "from rdflib import Namespace\n",
    "\n",
    "prefixes = {\n",
    "    'gtpo': Namespace('https://rdf.guidetopharmacology.org/ns/gtpo#'),\n",
    "    'grac': Namespace('https://rdf.guidetopharmacology.org/GRAC/'),\n",
    "    'cito': Namespace('http://purl.org/spar/cito/'),\n",
    "    'dcat': Namespace('http://www.w3.org/ns/dcat#'),\n",
    "    'dctypes': Namespace('http://purl.org/dc/dcmitype/'),\n",
    "    'dct': Namespace('http://purl.org/dc/terms/'),\n",
    "    'foaf': Namespace('http://xmlns.com/foaf/0.1/'),\n",
    "    'freq': Namespace('http://purl.org/cld/freq/'),\n",
    "    'idot': Namespace('http://identifiers.org/idot/'),\n",
    "    'lexvo': Namespace('http://lexvo.org/ontology#'),\n",
    "    'pav': Namespace('http://purl.org/pav/'),\n",
    "    'prov': Namespace('http://www.w3.org/ns/prov#'),\n",
    "    'rdf': Namespace('http://www.w3.org/1999/02/22-rdf-syntax-ns#'),\n",
    "    'rdfs': Namespace('http://www.w3.org/2000/01/rdf-schema#'),\n",
    "    'schemaorg': Namespace('http://schema.org/'),\n",
    "    'sd': Namespace('http://www.w3.org/ns/sparql-service-description#'),\n",
    "    'sio': Namespace('http://semanticscience.org/resource/'),\n",
    "    'void': Namespace('http://rdfs.org/ns/void#'),\n",
    "    'void-ext': Namespace('http://ldf.fi/void-ext#'),\n",
    "    'xsd': Namespace('http://www.w3.org/2001/XMLSchema#'),\n",
    "    # Add other required prefixes based on your data inspection\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "id": "r5orIl8kkLaZ",
    "pycharm": {
     "name": "#%%\n"
    }
   },
   "outputs": [],
   "source": [
    "config = Neo4jStoreConfig(auth_data=auth_data,\n",
    "                          custom_prefixes=prefixes,\n",
    "                          handle_vocab_uri_strategy=HANDLE_VOCAB_URI_STRATEGY.IGNORE,\n",
    "                          batching=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "dkT27dtL_Ag7"
   },
   "source": [
    "## Load the ontology data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 373
    },
    "id": "07lRVHQ7kLaZ",
    "outputId": "18addd39-7511-4801-de0f-39b241e156fc",
    "pycharm": {
     "name": "#%%\n"
    }
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Uniqueness constraint on :Resource(uri) found. \n",
      "                \n",
      "                \n",
      "The store is now: Open\n",
      "The store is now: Closed\n",
      "IMPORTED 387357 TRIPLES\n"
     ]
    }
   ],
   "source": [
    "from rdflib_neo4j import Neo4jStore\n",
    "from rdflib import Graph\n",
    "file_path = 'https://www.guidetopharmacology.org/DATA/rdf/2024.2/gtp-rdf.n3'\n",
    "\n",
    "graph_store = Graph(store=Neo4jStore(config=config))\n",
    "graph_store.parse(file_path,format=\"nt\")\n",
    "graph_store.close(True)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "xrvCxjtZRUT0"
   },
   "source": [
    "This setup process installs the necessary libraries, defines authentication data, sets up namespaces, and loads the Guide to Pharmacology ontology data into a Neo4j graph database."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "zc_PvQad_Lzs"
   },
   "source": [
    "## Querying the Guide to Pharmacology data\n",
    "\n",
    "Now, let's explore the GtoP database data using a Cypher query:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {
    "id": "cx7CAGZN5yBN"
   },
   "outputs": [],
   "source": [
    "from neo4j import GraphDatabase\n",
    "\n",
    "# Initialize Neo4j driver\n",
    "driver = GraphDatabase.driver(\n",
    "    NEO_DB_URI,\n",
    "    auth=(NEO_DB_USERNAME, NEO_DB_PWD)\n",
    ")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Setup reused functions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "def run_cypher_query(query):\n",
    "    with driver.session(database=\"neo4j\") as session:\n",
    "        result = session.run(query)\n",
    "        # Fetch all results and convert them into a list of dictionaries\n",
    "        return [record.data() for record in result]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {
    "id": "xTEIt5Ifz4WW"
   },
   "outputs": [],
   "source": [
    "cypher_query = \"\"\"\n",
    "WITH [\"EnzymeTargetFamily\",\n",
    "      \"OtherProteinTargetFamily\",\n",
    "      \"TransporterTargetFamily\",\n",
    "      \"GProteinCoupledReceptorTargetFamily\",\n",
    "      \"CatalyticReceptorTargetFamily\",\n",
    "      \"LigandGatedIonChannelTargetFamily\",\n",
    "      \"VoltageGatedIonChannelTargetFamily\",\n",
    "      \"NuclearHormoneReceptorTargetFamily\",\n",
    "      \"OtherIonChannelTargetFamily\",\n",
    "      \"GroupingTargetFamily\",\n",
    "      \"LigandTargetFamily\"] AS targetFamilyTypes,\n",
    "\n",
    "     [\"SyntheticOrganicLigand\",\n",
    "      \"NaturalProductLigand\",\n",
    "      \"PeptideLigand\",\n",
    "      \"MetaboliteLigand\",\n",
    "      \"AntibodyLigand\",\n",
    "      \"InorganicLigand\"] AS ligandTypes,\n",
    "\n",
    "     [\"AntagonistInteraction\",\n",
    "      \"AgonistInteraction\",\n",
    "      \"ActivatorInteraction\",\n",
    "      \"Interaction\",\n",
    "      \"InhibitorInteraction\",\n",
    "      \"AntibodyInteraction\",\n",
    "      \"ChannelBlockerInteraction\",\n",
    "      \"AllostericModulatorInteraction\",\n",
    "      \"GatingInhibitorInteraction\",\n",
    "      \"SubunitSpecificInteraction\"] AS interactionTypes\n",
    "\n",
    "UNWIND targetFamilyTypes AS targetFamilyType\n",
    "UNWIND ligandTypes AS ligandType\n",
    "UNWIND interactionTypes AS interactionType\n",
    "\n",
    "CALL apoc.cypher.run(\"\n",
    "    MATCH (tf:`\" + targetFamilyType + \"` {label: $label})<-[r1:hasTargetFamily]-(t:Target)\n",
    "    MATCH (i:`\" + interactionType + \"`)-[r2:hasTarget]->(t)\n",
    "    MATCH (i)-[r3:hasLigand]->(l:`\" + ligandType + \"`)\n",
    "    RETURN tf, r1, t, r2, i, r3, l\n",
    "    LIMIT 30\n",
    "\", {label: \"STE7 family\"}) YIELD value\n",
    "\n",
    "RETURN value.tf AS tf, value.r1 AS r1, value.t AS t, value.r2 AS r2, value.i AS i, value.r3 AS r3, value.l AS l\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {
    "id": "Fk2n5A_H560x"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88688'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'COc1ccc(cc1)[C@H]1CC(=O)c2c1c(OC)cc(c2)OC',\n",
      "        'comment': '(R)-STU104 is a first-in-class molecule that inhibits the '\n",
      "                   'interaction between the proteins kinases TAK1 '\n",
      "                   '(mitogen-activated protein kinase kinase kinase 7; MAP3K7) '\n",
      "                   'and MKK3 (mitogen-activated protein kinase kinase 3; '\n",
      "                   'MAP2K3) <Reference id=43711/>. These kinases are part of '\n",
      "                   'the inflammatory signalling cascade that culminates in '\n",
      "                   'TNF-&alpha; production. (R)-STU104 binds to MKK3 at a '\n",
      "                   'location that disrupts its interaction with the upstream '\n",
      "                   'kinase TAK1. This action perturbs MKK3 phosphorylation by '\n",
      "                   'TAK1 and inhibits downstream signal propagation.  Blocking '\n",
      "                   'TAK1-mediated phosphorylation of MKK3 with (R)-STU104 '\n",
      "                   'reduces TNF-&alpha; <i>in vitro</i> and in mouse models of '\n",
      "                   'chronic ulcerative colitis (UC). In the mouse models '\n",
      "                   '(R)-STU104 was a more effective UC treatment than the '\n",
      "                   'approved UC drug <Ligand id=2700/> (a PPAR&gamma; '\n",
      "                   'inhibitor). In addition to TNF-&alpha;, (R)-STU104 reduced '\n",
      "                   'production of several pro-inflammatory cytokines <i>in '\n",
      "                   'vivo</i>, including IL-1&beta;, IL-6, and IL-23.',\n",
      "        'inChI': 'InChI=1S/C18H18O4/c1-20-12-6-4-11(5-7-12)14-10-16(19)15-8-13(21-2)9-17(22-3)18(14)15/h4-9,14H,10H2,1-3H3/t14-/m1/s1',\n",
      "        'inChIKey': 'OYJBHGSSAJNKJF-CQSZACIVSA-N',\n",
      "        'isomericSMILES': 'O=C1C[C@H](c2ccc(OC)cc2)c2c(OC)cc(OC)cc12',\n",
      "        'iupacName': '(3R)-4,6-dimethoxy-3-(4-methoxyphenyl)-2,3-dihydroinden-1-one',\n",
      "        'label': '(R)-STU104',\n",
      "        'ligandName': '(R)-STU104',\n",
      "        'synonym': '(R)-4e [PMID: 35442672]',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand12006'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 3',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 3',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2064'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88688'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 3',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 3',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2064'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88688'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'COc1ccc(cc1)[C@H]1CC(=O)c2c1c(OC)cc(c2)OC',\n",
      "          'comment': '(R)-STU104 is a first-in-class molecule that inhibits '\n",
      "                     'the interaction between the proteins kinases TAK1 '\n",
      "                     '(mitogen-activated protein kinase kinase kinase 7; '\n",
      "                     'MAP3K7) and MKK3 (mitogen-activated protein kinase '\n",
      "                     'kinase 3; MAP2K3) <Reference id=43711/>. These kinases '\n",
      "                     'are part of the inflammatory signalling cascade that '\n",
      "                     'culminates in TNF-&alpha; production. (R)-STU104 binds '\n",
      "                     'to MKK3 at a location that disrupts its interaction with '\n",
      "                     'the upstream kinase TAK1. This action perturbs MKK3 '\n",
      "                     'phosphorylation by TAK1 and inhibits downstream signal '\n",
      "                     'propagation.  Blocking TAK1-mediated phosphorylation of '\n",
      "                     'MKK3 with (R)-STU104 reduces TNF-&alpha; <i>in vitro</i> '\n",
      "                     'and in mouse models of chronic ulcerative colitis (UC). '\n",
      "                     'In the mouse models (R)-STU104 was a more effective UC '\n",
      "                     'treatment than the approved UC drug <Ligand id=2700/> (a '\n",
      "                     'PPAR&gamma; inhibitor). In addition to TNF-&alpha;, '\n",
      "                     '(R)-STU104 reduced production of several '\n",
      "                     'pro-inflammatory cytokines <i>in vivo</i>, including '\n",
      "                     'IL-1&beta;, IL-6, and IL-23.',\n",
      "          'inChI': 'InChI=1S/C18H18O4/c1-20-12-6-4-11(5-7-12)14-10-16(19)15-8-13(21-2)9-17(22-3)18(14)15/h4-9,14H,10H2,1-3H3/t14-/m1/s1',\n",
      "          'inChIKey': 'OYJBHGSSAJNKJF-CQSZACIVSA-N',\n",
      "          'isomericSMILES': 'O=C1C[C@H](c2ccc(OC)cc2)c2c(OC)cc(OC)cc12',\n",
      "          'iupacName': '(3R)-4,6-dimethoxy-3-(4-methoxyphenyl)-2,3-dihydroinden-1-one',\n",
      "          'label': '(R)-STU104',\n",
      "          'ligandName': '(R)-STU104',\n",
      "          'synonym': '(R)-4e [PMID: 35442672]',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand12006'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 3',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 3',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2064'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction82790'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'N#CC(=C(Sc1ccccc1N)N)c1cccc(c1)C(c1ccncc1)O',\n",
      "        'comment': 'This is compound 41 in <Reference id=25918/>.',\n",
      "        'inChI': 'InChI=1S/C21H18N4OS/c22-13-17(21(24)27-19-7-2-1-6-18(19)23)15-4-3-5-16(12-15)20(26)14-8-10-25-11-9-14/h1-12,20,26H,23-24H2/b21-17+',\n",
      "        'inChIKey': 'NHBMKTBZZSJUGA-HEHNFIMWSA-N',\n",
      "        'isomericSMILES': 'N#C/C(=C(/Sc1ccccc1N)/N)/c1cccc(c1)C(c1ccncc1)O',\n",
      "        'iupacName': '(2Z)-3-amino-3-[(2-aminophenyl)sulfanyl]-2-{3-[hydroxy(pyridin-4-yl)methyl]phenyl}prop-2-enenitrile',\n",
      "        'label': 'MEK inhibitor I',\n",
      "        'ligandName': 'MEK inhibitor I',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6006'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 3',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 3',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2064'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction82790'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 3',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 3',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2064'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction82790'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'N#CC(=C(Sc1ccccc1N)N)c1cccc(c1)C(c1ccncc1)O',\n",
      "          'comment': 'This is compound 41 in <Reference id=25918/>.',\n",
      "          'inChI': 'InChI=1S/C21H18N4OS/c22-13-17(21(24)27-19-7-2-1-6-18(19)23)15-4-3-5-16(12-15)20(26)14-8-10-25-11-9-14/h1-12,20,26H,23-24H2/b21-17+',\n",
      "          'inChIKey': 'NHBMKTBZZSJUGA-HEHNFIMWSA-N',\n",
      "          'isomericSMILES': 'N#C/C(=C(/Sc1ccccc1N)/N)/c1cccc(c1)C(c1ccncc1)O',\n",
      "          'iupacName': '(2Z)-3-amino-3-[(2-aminophenyl)sulfanyl]-2-{3-[hydroxy(pyridin-4-yl)methyl]phenyl}prop-2-enenitrile',\n",
      "          'label': 'MEK inhibitor I',\n",
      "          'ligandName': 'MEK inhibitor I',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6006'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 3',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 3',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2064'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85270'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'N#Cc1ccnc(c1)Nc1cc(n(n1)C1CCCC1)C1CCN(CC1)C1COC1',\n",
      "        'comment': 'Compound 11 is a potent, selective, and brain penetrant '\n",
      "                   'inhibitor of dual leucine zipper kinase (DLK, '\n",
      "                   '<i>MAP3K12</i>) <Reference id=35254/>. DLK inhibitors are '\n",
      "                   'being investigated for neuroprotective potential.',\n",
      "        'inChI': 'InChI=1S/C22H28N6O/c23-13-16-5-8-24-21(11-16)25-22-12-20(28(26-22)18-3-1-2-4-18)17-6-9-27(10-7-17)19-14-29-15-19/h5,8,11-12,17-19H,1-4,6-7,9-10,14-15H2,(H,24,25,26)',\n",
      "        'inChIKey': 'GMTAOJMPNXLKJI-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'N#Cc1ccnc(c1)Nc1cc(n(n1)C1CCCC1)C1CCN(CC1)C1COC1',\n",
      "        'iupacName': '2-[[1-cyclopentyl-5-[1-(oxetan-3-yl)piperidin-4-yl]pyrazol-3-yl]amino]pyridine-4-carbonitrile',\n",
      "        'label': 'compound 11 [PMID: 26431428]',\n",
      "        'ligandName': 'compound 11 [PMID: 26431428]',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9989'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 7',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 7',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2068'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85270'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 7',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 7',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2068'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85270'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'N#Cc1ccnc(c1)Nc1cc(n(n1)C1CCCC1)C1CCN(CC1)C1COC1',\n",
      "          'comment': 'Compound 11 is a potent, selective, and brain penetrant '\n",
      "                     'inhibitor of dual leucine zipper kinase (DLK, '\n",
      "                     '<i>MAP3K12</i>) <Reference id=35254/>. DLK inhibitors '\n",
      "                     'are being investigated for neuroprotective potential.',\n",
      "          'inChI': 'InChI=1S/C22H28N6O/c23-13-16-5-8-24-21(11-16)25-22-12-20(28(26-22)18-3-1-2-4-18)17-6-9-27(10-7-17)19-14-29-15-19/h5,8,11-12,17-19H,1-4,6-7,9-10,14-15H2,(H,24,25,26)',\n",
      "          'inChIKey': 'GMTAOJMPNXLKJI-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'N#Cc1ccnc(c1)Nc1cc(n(n1)C1CCCC1)C1CCN(CC1)C1COC1',\n",
      "          'iupacName': '2-[[1-cyclopentyl-5-[1-(oxetan-3-yl)piperidin-4-yl]pyrazol-3-yl]amino]pyridine-4-carbonitrile',\n",
      "          'label': 'compound 11 [PMID: 26431428]',\n",
      "          'ligandName': 'compound 11 [PMID: 26431428]',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9989'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 7',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 7',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2068'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88821'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'C=CC(=O)N1CCC[C@H](C1)n1nc(c2c1ncnc2N)c1nnn(c1)CC(c1ccccc1)(F)F',\n",
      "        'comment': 'This compound is a mitogen-activated protein kinase kinase '\n",
      "                   '7 (MKK7; <i>MAP2K7</i>) inhibitor <Reference id=43961/>.  '\n",
      "                   'MKK7 exclusively phosphorylates downstream JNK, and '\n",
      "                   'represents an attractive molecular target for selectively '\n",
      "                   'modifying JNK signalling in human disease. 1K is suitable '\n",
      "                   'for <i>in vitro</i> work but its physicochemical '\n",
      "                   'properties would need to be optimised further for <i>in '\n",
      "                   'vivo</i> applications.',\n",
      "        'inChI': 'InChI=1S/C23H23F2N9O/c1-2-18(35)32-10-6-9-16(11-32)34-22-19(21(26)27-14-28-22)20(30-34)17-12-33(31-29-17)13-23(24,25)15-7-4-3-5-8-15/h2-5,7-8,12,14,16H,1,6,9-11,13H2,(H2,26,27,28)/t16-/m1/s1',\n",
      "        'inChIKey': 'DGJMHKMYSDYOFP-MRXNPFEDSA-N',\n",
      "        'isomericSMILES': 'Nc1c2c(ncn1)n(nc2c1nnn(c1)CC(c1ccccc1)(F)F)[C@H]1CN(CCC1)C(=O)C=C',\n",
      "        'iupacName': '(R)-1-(3-(4-Amino-3-(1-(2,2-difluoro-2-phenylethyl)-1H-1,2,3-triazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one',\n",
      "        'label': 'compound 1k [PMID: 35912476]',\n",
      "        'ligandName': 'compound 1k [PMID: 35912476]',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand12104'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 7',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 7',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2068'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88821'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 7',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 7',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2068'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88821'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'C=CC(=O)N1CCC[C@H](C1)n1nc(c2c1ncnc2N)c1nnn(c1)CC(c1ccccc1)(F)F',\n",
      "          'comment': 'This compound is a mitogen-activated protein kinase '\n",
      "                     'kinase 7 (MKK7; <i>MAP2K7</i>) inhibitor <Reference '\n",
      "                     'id=43961/>.  MKK7 exclusively phosphorylates downstream '\n",
      "                     'JNK, and represents an attractive molecular target for '\n",
      "                     'selectively modifying JNK signalling in human disease. '\n",
      "                     '1K is suitable for <i>in vitro</i> work but its '\n",
      "                     'physicochemical properties would need to be optimised '\n",
      "                     'further for <i>in vivo</i> applications.',\n",
      "          'inChI': 'InChI=1S/C23H23F2N9O/c1-2-18(35)32-10-6-9-16(11-32)34-22-19(21(26)27-14-28-22)20(30-34)17-12-33(31-29-17)13-23(24,25)15-7-4-3-5-8-15/h2-5,7-8,12,14,16H,1,6,9-11,13H2,(H2,26,27,28)/t16-/m1/s1',\n",
      "          'inChIKey': 'DGJMHKMYSDYOFP-MRXNPFEDSA-N',\n",
      "          'isomericSMILES': 'Nc1c2c(ncn1)n(nc2c1nnn(c1)CC(c1ccccc1)(F)F)[C@H]1CN(CCC1)C(=O)C=C',\n",
      "          'iupacName': '(R)-1-(3-(4-Amino-3-(1-(2,2-difluoro-2-phenylethyl)-1H-1,2,3-triazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one',\n",
      "          'label': 'compound 1k [PMID: 35912476]',\n",
      "          'ligandName': 'compound 1k [PMID: 35912476]',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand12104'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 7',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 7',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2068'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79558'},\n",
      "  'l': {'approved': 't',\n",
      "        'canonicalSMILES': 'CC(=O)Nc1cccc(c1)n1c(=O)n(C2CC2)c(=O)c2c1c(C)c(=O)n(c2Nc1ccc(cc1F)I)C',\n",
      "        'comment': 'Trametinib is a Type-3 kinase inhibitor. Marketed '\n",
      "                   'formulations contain trametinib dimethyl sulfoxide '\n",
      "                   '(PubChem <a '\n",
      "                   'href=%22https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=50992434%22>CID '\n",
      "                   '50992434</a>).',\n",
      "        'inChI': 'InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)',\n",
      "        'inChIKey': 'LIRYPHYGHXZJBZ-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'CC(=O)Nc1cccc(c1)n1c(=O)n(C2CC2)c(=O)c2c1c(C)c(=O)n(c2Nc1ccc(cc1F)I)C',\n",
      "        'iupacName': 'N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide',\n",
      "        'label': 'trametinib',\n",
      "        'ligandName': 'trametinib',\n",
      "        'synonym': 'trametinib dimethyl sulfoxide',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6495'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79558'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79558'},\n",
      "         'hasLigand',\n",
      "         {'approved': 't',\n",
      "          'canonicalSMILES': 'CC(=O)Nc1cccc(c1)n1c(=O)n(C2CC2)c(=O)c2c1c(C)c(=O)n(c2Nc1ccc(cc1F)I)C',\n",
      "          'comment': 'Trametinib is a Type-3 kinase inhibitor. Marketed '\n",
      "                     'formulations contain trametinib dimethyl sulfoxide '\n",
      "                     '(PubChem <a '\n",
      "                     'href=%22https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=50992434%22>CID '\n",
      "                     '50992434</a>).',\n",
      "          'inChI': 'InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)',\n",
      "          'inChIKey': 'LIRYPHYGHXZJBZ-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'CC(=O)Nc1cccc(c1)n1c(=O)n(C2CC2)c(=O)c2c1c(C)c(=O)n(c2Nc1ccc(cc1F)I)C',\n",
      "          'iupacName': 'N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide',\n",
      "          'label': 'trametinib',\n",
      "          'ligandName': 'trametinib',\n",
      "          'synonym': 'trametinib dimethyl sulfoxide',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6495'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80509'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'N#CC(=C(Sc1ccccc1N)N)c1cccc(c1)C(c1ccncc1)O',\n",
      "        'comment': 'This is compound 41 in <Reference id=25918/>.',\n",
      "        'inChI': 'InChI=1S/C21H18N4OS/c22-13-17(21(24)27-19-7-2-1-6-18(19)23)15-4-3-5-16(12-15)20(26)14-8-10-25-11-9-14/h1-12,20,26H,23-24H2/b21-17+',\n",
      "        'inChIKey': 'NHBMKTBZZSJUGA-HEHNFIMWSA-N',\n",
      "        'isomericSMILES': 'N#C/C(=C(/Sc1ccccc1N)/N)/c1cccc(c1)C(c1ccncc1)O',\n",
      "        'iupacName': '(2Z)-3-amino-3-[(2-aminophenyl)sulfanyl]-2-{3-[hydroxy(pyridin-4-yl)methyl]phenyl}prop-2-enenitrile',\n",
      "        'label': 'MEK inhibitor I',\n",
      "        'ligandName': 'MEK inhibitor I',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6006'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80509'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80509'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'N#CC(=C(Sc1ccccc1N)N)c1cccc(c1)C(c1ccncc1)O',\n",
      "          'comment': 'This is compound 41 in <Reference id=25918/>.',\n",
      "          'inChI': 'InChI=1S/C21H18N4OS/c22-13-17(21(24)27-19-7-2-1-6-18(19)23)15-4-3-5-16(12-15)20(26)14-8-10-25-11-9-14/h1-12,20,26H,23-24H2/b21-17+',\n",
      "          'inChIKey': 'NHBMKTBZZSJUGA-HEHNFIMWSA-N',\n",
      "          'isomericSMILES': 'N#C/C(=C(/Sc1ccccc1N)/N)/c1cccc(c1)C(c1ccncc1)O',\n",
      "          'iupacName': '(2Z)-3-amino-3-[(2-aminophenyl)sulfanyl]-2-{3-[hydroxy(pyridin-4-yl)methyl]phenyl}prop-2-enenitrile',\n",
      "          'label': 'MEK inhibitor I',\n",
      "          'ligandName': 'MEK inhibitor I',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6006'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80512'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'O=C1CCC(=O)N1C1=C(Cl)C(=O)c2c(C1=O)cccc2',\n",
      "        'inChI': 'InChI=1S/C14H8ClNO4/c15-11-12(16-9(17)5-6-10(16)18)14(20)8-4-2-1-3-7(8)13(11)19/h1-4H,5-6H2',\n",
      "        'inChIKey': 'GYQSWJNGTWVFOL-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'O=C1CCC(=O)N1C1=C(Cl)C(=O)c2c(C1=O)cccc2',\n",
      "        'iupacName': '1-(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)pyrrolidine-2,5-dione',\n",
      "        'label': 'MEK inhibitor II',\n",
      "        'ligandName': 'MEK inhibitor II',\n",
      "        'synonym': 'NSC686549',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6007'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80512'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80512'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'O=C1CCC(=O)N1C1=C(Cl)C(=O)c2c(C1=O)cccc2',\n",
      "          'inChI': 'InChI=1S/C14H8ClNO4/c15-11-12(16-9(17)5-6-10(16)18)14(20)8-4-2-1-3-7(8)13(11)19/h1-4H,5-6H2',\n",
      "          'inChIKey': 'GYQSWJNGTWVFOL-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'O=C1CCC(=O)N1C1=C(Cl)C(=O)c2c(C1=O)cccc2',\n",
      "          'iupacName': '1-(3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)pyrrolidine-2,5-dione',\n",
      "          'label': 'MEK inhibitor II',\n",
      "          'ligandName': 'MEK inhibitor II',\n",
      "          'synonym': 'NSC686549',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6007'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80667'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'CCNc1cc2C=CCC(O)C(O)C(=O)C=CC(C(OC(=O)c2c(c1)O)C)C',\n",
      "        'comment': 'The discovery of E6201 is described in <Reference '\n",
      "                   'id=26049/>. It is a fully synthetic analogue of the '\n",
      "                   'naturally occurring fungal resorcylic lactone LL-Z1640-2 '\n",
      "                   '(PubChem <a '\n",
      "                   'href=%22https://pubchem.ncbi.nlm.nih.gov/compound/9863776?from=summary%22>CID '\n",
      "                   '9863776</a>).',\n",
      "        'inChI': 'InChI=1S/C21H27NO6/c1-4-22-15-10-14-6-5-7-16(23)20(26)17(24)9-8-12(2)13(3)28-21(27)19(14)18(25)11-15/h5-6,8-13,16,20,22-23,25-26H,4,7H2,1-3H3/b6-5+,9-8-/t12-,13+,16+,20+/m1/s1',\n",
      "        'inChIKey': 'MWUFVYLAWAXDHQ-HMNLTAHHSA-N',\n",
      "        'isomericSMILES': 'CCNc1cc2/C=C/C[C@H](O)[C@H](O)C(=O)/C=C/[C@H]([C@@H](OC(=O)c2c(c1)O)C)C',\n",
      "        'iupacName': '(4S,5R,6Z,9S,10S,12E)-16-ethylamino-9,10,18-trihydroxy-4,5-dimethyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione',\n",
      "        'label': 'E6201',\n",
      "        'ligandName': 'E6201',\n",
      "        'synonym': 'E-6201',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7836'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80667'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80667'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'CCNc1cc2C=CCC(O)C(O)C(=O)C=CC(C(OC(=O)c2c(c1)O)C)C',\n",
      "          'comment': 'The discovery of E6201 is described in <Reference '\n",
      "                     'id=26049/>. It is a fully synthetic analogue of the '\n",
      "                     'naturally occurring fungal resorcylic lactone LL-Z1640-2 '\n",
      "                     '(PubChem <a '\n",
      "                     'href=%22https://pubchem.ncbi.nlm.nih.gov/compound/9863776?from=summary%22>CID '\n",
      "                     '9863776</a>).',\n",
      "          'inChI': 'InChI=1S/C21H27NO6/c1-4-22-15-10-14-6-5-7-16(23)20(26)17(24)9-8-12(2)13(3)28-21(27)19(14)18(25)11-15/h5-6,8-13,16,20,22-23,25-26H,4,7H2,1-3H3/b6-5+,9-8-/t12-,13+,16+,20+/m1/s1',\n",
      "          'inChIKey': 'MWUFVYLAWAXDHQ-HMNLTAHHSA-N',\n",
      "          'isomericSMILES': 'CCNc1cc2/C=C/C[C@H](O)[C@H](O)C(=O)/C=C/[C@H]([C@@H](OC(=O)c2c(c1)O)C)C',\n",
      "          'iupacName': '(4S,5R,6Z,9S,10S,12E)-16-ethylamino-9,10,18-trihydroxy-4,5-dimethyl-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione',\n",
      "          'label': 'E6201',\n",
      "          'ligandName': 'E6201',\n",
      "          'synonym': 'E-6201',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7836'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80833'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'OCC(CONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "        'comment': 'Mirdametinib (PD 0325901) is a selective and non '\n",
      "                   'ATP-competitive MEK inhibitor <Reference id=26251/>.',\n",
      "        'inChI': 'InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1',\n",
      "        'inChIKey': 'SUDAHWBOROXANE-SECBINFHSA-N',\n",
      "        'isomericSMILES': 'OC[C@H](CONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "        'iupacName': 'N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide',\n",
      "        'label': 'mirdametinib',\n",
      "        'ligandName': 'mirdametinib',\n",
      "        'synonym': 'PD 0325901',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7935'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80833'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80833'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'OCC(CONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "          'comment': 'Mirdametinib (PD 0325901) is a selective and non '\n",
      "                     'ATP-competitive MEK inhibitor <Reference id=26251/>.',\n",
      "          'inChI': 'InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1',\n",
      "          'inChIKey': 'SUDAHWBOROXANE-SECBINFHSA-N',\n",
      "          'isomericSMILES': 'OC[C@H](CONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "          'iupacName': 'N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide',\n",
      "          'label': 'mirdametinib',\n",
      "          'ligandName': 'mirdametinib',\n",
      "          'synonym': 'PD 0325901',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7935'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85067'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'OCCONC(=O)c1ccc2n(c1Nc1ccc(cc1F)I)cnc2',\n",
      "        'comment': 'GDC-0623 (RG-7420) is an ATP-uncompetitive MEK1 inhibitor '\n",
      "                   'that was developed by Genentech for anti-cancer potential '\n",
      "                   '<Reference id=34885/>. The structure of GDC-0623 was '\n",
      "                   \"disclosed for the first time in 'Supplementary Figure 1a' \"\n",
      "                   'provided with Hatzivassiliou <i>et al</i>. (2013) '\n",
      "                   '<Reference id=34886/>.',\n",
      "        'inChI': 'InChI=1S/C16H14FIN4O3/c17-13-7-10(18)1-4-14(13)20-15-12(16(24)21-25-6-5-23)3-2-11-8-19-9-22(11)15/h1-4,7-9,20,23H,5-6H2,(H,21,24)',\n",
      "        'inChIKey': 'RFWVETIZUQEJEF-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'OCCONC(=O)c1ccc2n(c1Nc1ccc(cc1F)I)cnc2',\n",
      "        'label': 'GDC-0623',\n",
      "        'ligandName': 'GDC-0623',\n",
      "        'synonym': 'G-868',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9909'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85067'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85067'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'OCCONC(=O)c1ccc2n(c1Nc1ccc(cc1F)I)cnc2',\n",
      "          'comment': 'GDC-0623 (RG-7420) is an ATP-uncompetitive MEK1 '\n",
      "                     'inhibitor that was developed by Genentech for '\n",
      "                     'anti-cancer potential <Reference id=34885/>. The '\n",
      "                     'structure of GDC-0623 was disclosed for the first time '\n",
      "                     \"in 'Supplementary Figure 1a' provided with \"\n",
      "                     'Hatzivassiliou <i>et al</i>. (2013) <Reference '\n",
      "                     'id=34886/>.',\n",
      "          'inChI': 'InChI=1S/C16H14FIN4O3/c17-13-7-10(18)1-4-14(13)20-15-12(16(24)21-25-6-5-23)3-2-11-8-19-9-22(11)15/h1-4,7-9,20,23H,5-6H2,(H,21,24)',\n",
      "          'inChIKey': 'RFWVETIZUQEJEF-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'OCCONC(=O)c1ccc2n(c1Nc1ccc(cc1F)I)cnc2',\n",
      "          'label': 'GDC-0623',\n",
      "          'ligandName': 'GDC-0623',\n",
      "          'synonym': 'G-868',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9909'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85068'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'OCCONC(=O)c1cc(CN2OCCCC2=O)c(c(c1Nc1ccc(cc1F)I)F)F',\n",
      "        'comment': 'CH4987655 is an orally active allosteric MEK inhibitor '\n",
      "                   'that was designed as a novel cancer chemotherapeutic '\n",
      "                   '<Reference id=34887/>.',\n",
      "        'inChI': 'InChI=1S/C20H19F3IN3O5/c21-14-9-12(24)3-4-15(14)25-19-13(20(30)26-31-7-5-28)8-11(17(22)18(19)23)10-27-16(29)2-1-6-32-27/h3-4,8-9,25,28H,1-2,5-7,10H2,(H,26,30)',\n",
      "        'inChIKey': 'FIMYFEGKMOCQKT-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'OCCONC(=O)c1cc(CN2OCCCC2=O)c(c(c1Nc1ccc(cc1F)I)F)F',\n",
      "        'iupacName': '3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide',\n",
      "        'label': 'CH4987655',\n",
      "        'ligandName': 'CH4987655',\n",
      "        'synonym': 'compound 24 [PMID: 21316218]',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9910'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85068'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85068'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'OCCONC(=O)c1cc(CN2OCCCC2=O)c(c(c1Nc1ccc(cc1F)I)F)F',\n",
      "          'comment': 'CH4987655 is an orally active allosteric MEK inhibitor '\n",
      "                     'that was designed as a novel cancer chemotherapeutic '\n",
      "                     '<Reference id=34887/>.',\n",
      "          'inChI': 'InChI=1S/C20H19F3IN3O5/c21-14-9-12(24)3-4-15(14)25-19-13(20(30)26-31-7-5-28)8-11(17(22)18(19)23)10-27-16(29)2-1-6-32-27/h3-4,8-9,25,28H,1-2,5-7,10H2,(H,26,30)',\n",
      "          'inChIKey': 'FIMYFEGKMOCQKT-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'OCCONC(=O)c1cc(CN2OCCCC2=O)c(c(c1Nc1ccc(cc1F)I)F)F',\n",
      "          'iupacName': '3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide',\n",
      "          'label': 'CH4987655',\n",
      "          'ligandName': 'CH4987655',\n",
      "          'synonym': 'compound 24 [PMID: 21316218]',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9910'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction86900'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'OC1CC(N(C1)C(=O)C(C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)C(=O)NC(c1ccc(cc1)c1scnc1C)C',\n",
      "        'comment': 'MS432 is the first-reported mitogen-activated protein '\n",
      "                   'kinase kinase 1/2 (MEK1/2) degrader <Reference id=38503/>. '\n",
      "                   'Structurally MS432 is a hybrid molecule, combining a '\n",
      "                   'kinase-targeting ligand (based on <Ligand id=7935/>) with '\n",
      "                   'a VHL-engaging moeity In this case VHL ligand 2, '\n",
      "                   '(<i>S,R,S</i>)-AHPC-Me  . These types of agents are known '\n",
      "                   'as PROTACs, or proteolysis targeting chimeras. It targets '\n",
      "                   'the kinases for VHL E3 ligase- and proteasome-mediated '\n",
      "                   'degradation. <i>In vitro</i>, the effect of MS432 is '\n",
      "                   'phenocopied by MEK1/2 knockdown. MS432 is bioavailable and '\n",
      "                   'suitable for <i>in vivo</i> studies.',\n",
      "        'inChI': 'InChI=1S/C50H65F3IN7O6S/c1-31(33-16-18-34(19-17-33)45-32(2)56-30-68-45)57-48(65)41-28-36(62)29-61(41)49(66)46(50(3,4)5)59-42(63)15-12-10-8-6-7-9-11-13-24-55-25-14-26-67-60-47(64)37-21-22-38(51)43(53)44(37)58-40-23-20-35(54)27-39(40)52/h16-23,27,30-31,36,41,46,55,58,62H,6-15,24-26,28-29H2,1-5H3,(H,57,65)(H,59,63)(H,60,64)/t31-,36+,41-,46+/m0/s1',\n",
      "        'inChIKey': 'KCBAMQOKOLXLOX-BSZYMOERSA-N',\n",
      "        'isomericSMILES': 'O[C@@H]1C[C@H](N(C1)C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)C(=O)N[C@H](c1ccc(cc1)c1scnc1C)C',\n",
      "        'iupacName': '(2S,4R)-1-((S)-20-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide',\n",
      "        'label': 'MS432',\n",
      "        'ligandName': 'MS432',\n",
      "        'synonym': 'compound 23 [PMID: 31730343]',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand10563'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction86900'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction86900'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'OC1CC(N(C1)C(=O)C(C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)C(=O)NC(c1ccc(cc1)c1scnc1C)C',\n",
      "          'comment': 'MS432 is the first-reported mitogen-activated protein '\n",
      "                     'kinase kinase 1/2 (MEK1/2) degrader <Reference '\n",
      "                     'id=38503/>. Structurally MS432 is a hybrid molecule, '\n",
      "                     'combining a kinase-targeting ligand (based on <Ligand '\n",
      "                     'id=7935/>) with a VHL-engaging moeity In this case VHL '\n",
      "                     'ligand 2, (<i>S,R,S</i>)-AHPC-Me  . These types of '\n",
      "                     'agents are known as PROTACs, or proteolysis targeting '\n",
      "                     'chimeras. It targets the kinases for VHL E3 ligase- and '\n",
      "                     'proteasome-mediated degradation. <i>In vitro</i>, the '\n",
      "                     'effect of MS432 is phenocopied by MEK1/2 knockdown. '\n",
      "                     'MS432 is bioavailable and suitable for <i>in vivo</i> '\n",
      "                     'studies.',\n",
      "          'inChI': 'InChI=1S/C50H65F3IN7O6S/c1-31(33-16-18-34(19-17-33)45-32(2)56-30-68-45)57-48(65)41-28-36(62)29-61(41)49(66)46(50(3,4)5)59-42(63)15-12-10-8-6-7-9-11-13-24-55-25-14-26-67-60-47(64)37-21-22-38(51)43(53)44(37)58-40-23-20-35(54)27-39(40)52/h16-23,27,30-31,36,41,46,55,58,62H,6-15,24-26,28-29H2,1-5H3,(H,57,65)(H,59,63)(H,60,64)/t31-,36+,41-,46+/m0/s1',\n",
      "          'inChIKey': 'KCBAMQOKOLXLOX-BSZYMOERSA-N',\n",
      "          'isomericSMILES': 'O[C@@H]1C[C@H](N(C1)C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)C(=O)N[C@H](c1ccc(cc1)c1scnc1C)C',\n",
      "          'iupacName': '(2S,4R)-1-((S)-20-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide',\n",
      "          'label': 'MS432',\n",
      "          'ligandName': 'MS432',\n",
      "          'synonym': 'compound 23 [PMID: 31730343]',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand10563'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88200'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'Ic1ccc(c(c1)Cl)Nc1c(ccc(c1F)F)C(=O)O',\n",
      "        'comment': 'We obtained the chemical structure for zapnometinib from '\n",
      "                   'WHO Proposed list 125 of July 2021. This mapped to PubChem '\n",
      "                   'CID 10112191, and <i>via</i> ChEMBL to the MEK '\n",
      "                   'serine/threonine protein kinases inhibitor PD-0184264 '\n",
      "                   '<Reference id=23016/>. is an oral MEK inhibitor that '\n",
      "                   'targets the Raf/MEK/ERK signalling pathway. This pathway '\n",
      "                   'is exploited (activated) by several species of RNA viruses '\n",
      "                   '(<i>e.g</i>. influenza viruses, hantaviruses, respiratory '\n",
      "                   'syncytial viruses and coronaviruses) for their successful '\n",
      "                   'replication. Blocking the host Raf/MEK/ERK signalling '\n",
      "                   'pathway inhibits formation of fully-formed virus particles '\n",
      "                   'in infected cells, and reduces viral load. At the same '\n",
      "                   'time, inhibiting MEK provides potential to modulate the '\n",
      "                   'immune response induced during infection. In COVID-19 '\n",
      "                   'zapnometinib is predicted to reduce expression of '\n",
      "                   'pro-inflammatory cytokines and/or chemokines (<i>e.g.</i> '\n",
      "                   'TNF-&alpha;, IL-1&beta;, CXCL10/IP-10, CXCL8/IL-8, '\n",
      "                   'CCL2/MCP-1 and CCL3/MIP-1&alpha;) that drive the '\n",
      "                   'destructive hyperinflammation in patients with severe '\n",
      "                   'disease.',\n",
      "        'inChI': 'InChI=1S/C13H7ClF2INO2/c14-8-5-6(17)1-4-10(8)18-12-7(13(19)20)2-3-9(15)11(12)16/h1-5,18H,(H,19,20)',\n",
      "        'inChIKey': 'XCNBGWKQXRQKSA-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'Clc1c(Nc2c(C(=O)O)ccc(c2F)F)ccc(c1)I',\n",
      "        'iupacName': '2-(2-chloro-4-iodoanilino)-3,4-difluorobenzoic acid',\n",
      "        'label': 'zapnometinib',\n",
      "        'ligandName': 'zapnometinib',\n",
      "        'synonym': 'ATR002',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand11679'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88200'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88200'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'Ic1ccc(c(c1)Cl)Nc1c(ccc(c1F)F)C(=O)O',\n",
      "          'comment': 'We obtained the chemical structure for zapnometinib from '\n",
      "                     'WHO Proposed list 125 of July 2021. This mapped to '\n",
      "                     'PubChem CID 10112191, and <i>via</i> ChEMBL to the MEK '\n",
      "                     'serine/threonine protein kinases inhibitor PD-0184264 '\n",
      "                     '<Reference id=23016/>. is an oral MEK inhibitor that '\n",
      "                     'targets the Raf/MEK/ERK signalling pathway. This pathway '\n",
      "                     'is exploited (activated) by several species of RNA '\n",
      "                     'viruses (<i>e.g</i>. influenza viruses, hantaviruses, '\n",
      "                     'respiratory syncytial viruses and coronaviruses) for '\n",
      "                     'their successful replication. Blocking the host '\n",
      "                     'Raf/MEK/ERK signalling pathway inhibits formation of '\n",
      "                     'fully-formed virus particles in infected cells, and '\n",
      "                     'reduces viral load. At the same time, inhibiting MEK '\n",
      "                     'provides potential to modulate the immune response '\n",
      "                     'induced during infection. In COVID-19 zapnometinib is '\n",
      "                     'predicted to reduce expression of pro-inflammatory '\n",
      "                     'cytokines and/or chemokines (<i>e.g.</i> TNF-&alpha;, '\n",
      "                     'IL-1&beta;, CXCL10/IP-10, CXCL8/IL-8, CCL2/MCP-1 and '\n",
      "                     'CCL3/MIP-1&alpha;) that drive the destructive '\n",
      "                     'hyperinflammation in patients with severe disease.',\n",
      "          'inChI': 'InChI=1S/C13H7ClF2INO2/c14-8-5-6(17)1-4-10(8)18-12-7(13(19)20)2-3-9(15)11(12)16/h1-5,18H,(H,19,20)',\n",
      "          'inChIKey': 'XCNBGWKQXRQKSA-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'Clc1c(Nc2c(C(=O)O)ccc(c2F)F)ccc(c1)I',\n",
      "          'iupacName': '2-(2-chloro-4-iodoanilino)-3,4-difluorobenzoic acid',\n",
      "          'label': 'zapnometinib',\n",
      "          'ligandName': 'zapnometinib',\n",
      "          'synonym': 'ATR002',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand11679'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88506'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'CNS(=O)(=O)Nc1nccc(c1F)Cc1c(=O)oc2c(c1C)ccc(c2)Oc1ncccn1',\n",
      "        'comment': 'Avutometinib (CH5126766; Ro5126766) is a small molecule '\n",
      "                   'that acts to inhibit p-MEK and p-ERK downstream of the '\n",
      "                   'c-RAF/MEK1 interaction <Reference id=43328/><Reference '\n",
      "                   'id=43329/>. It inhibits the proliferation of '\n",
      "                   'BRAF<sup>V600E</sup> and KRAS mutant cell lines <i>in '\n",
      "                   'vitro</i>. Avutometinib is orally active.',\n",
      "        'inChI': 'InChI=1S/C21H18FN5O5S/c1-12-15-5-4-14(31-21-25-7-3-8-26-21)11-17(15)32-20(28)16(12)10-13-6-9-24-19(18(13)22)27-33(29,30)23-2/h3-9,11,23H,10H2,1-2H3,(H,24,27)',\n",
      "        'inChIKey': 'LMMJFBMMJUMSJS-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'Fc1c(nccc1Cc1c(=O)oc2c(c1C)ccc(c2)Oc1ncccn1)NS(=O)(=O)NC',\n",
      "        'label': 'avutometinib',\n",
      "        'ligandName': 'avutometinib',\n",
      "        'synonym': 'VS-6766',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand11867'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88506'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88506'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'CNS(=O)(=O)Nc1nccc(c1F)Cc1c(=O)oc2c(c1C)ccc(c2)Oc1ncccn1',\n",
      "          'comment': 'Avutometinib (CH5126766; Ro5126766) is a small molecule '\n",
      "                     'that acts to inhibit p-MEK and p-ERK downstream of the '\n",
      "                     'c-RAF/MEK1 interaction <Reference id=43328/><Reference '\n",
      "                     'id=43329/>. It inhibits the proliferation of '\n",
      "                     'BRAF<sup>V600E</sup> and KRAS mutant cell lines <i>in '\n",
      "                     'vitro</i>. Avutometinib is orally active.',\n",
      "          'inChI': 'InChI=1S/C21H18FN5O5S/c1-12-15-5-4-14(31-21-25-7-3-8-26-21)11-17(15)32-20(28)16(12)10-13-6-9-24-19(18(13)22)27-33(29,30)23-2/h3-9,11,23H,10H2,1-2H3,(H,24,27)',\n",
      "          'inChIKey': 'LMMJFBMMJUMSJS-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'Fc1c(nccc1Cc1c(=O)oc2c(c1C)ccc(c2)Oc1ncccn1)NS(=O)(=O)NC',\n",
      "          'label': 'avutometinib',\n",
      "          'ligandName': 'avutometinib',\n",
      "          'synonym': 'VS-6766',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand11867'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88608'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'OCC(=O)N1CC[C@@H]([C@H](C1)F)n1c(C)nc2c1c1cc(c(cc1nc2)F)c1ccc(cc1Cl)Oc1ncccn1',\n",
      "        'comment': 'MAP855 is an orally active, ATP-competitive MEK1/2 '\n",
      "                   'inhibitor that was designed for anti-tumour potential '\n",
      "                   '<Reference id=43523/>. It inhibits wild-type and mutant '\n",
      "                   'forms of MEK1/2.',\n",
      "        'inChI': 'InChI=1S/C28H23ClF2N6O3/c1-15-35-24-12-34-23-11-21(30)18(17-4-3-16(9-20(17)29)40-28-32-6-2-7-33-28)10-19(23)27(24)37(15)25-5-8-36(13-22(25)31)26(39)14-38/h2-4,6-7,9-12,22,25,38H,5,8,13-14H2,1H3/t22-,25-/m0/s1',\n",
      "        'inChIKey': 'WZZBNLYBHUDSHF-DHLKQENFSA-N',\n",
      "        'isomericSMILES': 'Cc1nc2cnc3cc(c(cc3c2n1[C@H]1CCN(C[C@@H]1F)C(=O)CO)c1ccc(cc1Cl)Oc1ncccn1)F',\n",
      "        'iupacName': '1-[(3S,4S)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone',\n",
      "        'label': 'MAP855',\n",
      "        'ligandName': 'MAP855',\n",
      "        'synonym': 'compound 30 [PMID: 35195996]',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand11940'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88608'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88608'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'OCC(=O)N1CC[C@@H]([C@H](C1)F)n1c(C)nc2c1c1cc(c(cc1nc2)F)c1ccc(cc1Cl)Oc1ncccn1',\n",
      "          'comment': 'MAP855 is an orally active, ATP-competitive MEK1/2 '\n",
      "                     'inhibitor that was designed for anti-tumour potential '\n",
      "                     '<Reference id=43523/>. It inhibits wild-type and mutant '\n",
      "                     'forms of MEK1/2.',\n",
      "          'inChI': 'InChI=1S/C28H23ClF2N6O3/c1-15-35-24-12-34-23-11-21(30)18(17-4-3-16(9-20(17)29)40-28-32-6-2-7-33-28)10-19(23)27(24)37(15)25-5-8-36(13-22(25)31)26(39)14-38/h2-4,6-7,9-12,22,25,38H,5,8,13-14H2,1H3/t22-,25-/m0/s1',\n",
      "          'inChIKey': 'WZZBNLYBHUDSHF-DHLKQENFSA-N',\n",
      "          'isomericSMILES': 'Cc1nc2cnc3cc(c(cc3c2n1[C@H]1CCN(C[C@@H]1F)C(=O)CO)c1ccc(cc1Cl)Oc1ncccn1)F',\n",
      "          'iupacName': '1-[(3S,4S)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone',\n",
      "          'label': 'MAP855',\n",
      "          'ligandName': 'MAP855',\n",
      "          'synonym': 'compound 30 [PMID: 35195996]',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand11940'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80513'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'N#CC(=C(Sc1ccc(cc1)N)N)c1ccccc1C(F)(F)F',\n",
      "        'inChI': 'InChI=1S/C16H12F3N3S/c17-16(18,19)14-4-2-1-3-12(14)13(9-20)15(22)23-11-7-5-10(21)6-8-11/h1-8H,21-22H2/b15-13+',\n",
      "        'inChIKey': 'JLOXTZFYJNCPIS-FYWRMAATSA-N',\n",
      "        'isomericSMILES': 'N#C/C(=C(/Sc1ccc(cc1)N)/N)/c1ccccc1C(F)(F)F',\n",
      "        'iupacName': '(2Z)-3-amino-3-[(4-aminophenyl)sulfanyl]-2-[2-(trifluoromethyl)phenyl]prop-2-enenitrile',\n",
      "        'label': 'MEK1/2 inhibitor',\n",
      "        'ligandName': 'MEK1/2 inhibitor',\n",
      "        'synonym': 'SL-327',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6008'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80513'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80513'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'N#CC(=C(Sc1ccc(cc1)N)N)c1ccccc1C(F)(F)F',\n",
      "          'inChI': 'InChI=1S/C16H12F3N3S/c17-16(18,19)14-4-2-1-3-12(14)13(9-20)15(22)23-11-7-5-10(21)6-8-11/h1-8H,21-22H2/b15-13+',\n",
      "          'inChIKey': 'JLOXTZFYJNCPIS-FYWRMAATSA-N',\n",
      "          'isomericSMILES': 'N#C/C(=C(/Sc1ccc(cc1)N)/N)/c1ccccc1C(F)(F)F',\n",
      "          'iupacName': '(2Z)-3-amino-3-[(4-aminophenyl)sulfanyl]-2-[2-(trifluoromethyl)phenyl]prop-2-enenitrile',\n",
      "          'label': 'MEK1/2 inhibitor',\n",
      "          'ligandName': 'MEK1/2 inhibitor',\n",
      "          'synonym': 'SL-327',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6008'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81062'},\n",
      "  'l': {'approved': 't',\n",
      "        'canonicalSMILES': 'CC(=O)Nc1cccc(c1)n1c(=O)n(C2CC2)c(=O)c2c1c(C)c(=O)n(c2Nc1ccc(cc1F)I)C',\n",
      "        'comment': 'Trametinib is a Type-3 kinase inhibitor. Marketed '\n",
      "                   'formulations contain trametinib dimethyl sulfoxide '\n",
      "                   '(PubChem <a '\n",
      "                   'href=%22https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=50992434%22>CID '\n",
      "                   '50992434</a>).',\n",
      "        'inChI': 'InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)',\n",
      "        'inChIKey': 'LIRYPHYGHXZJBZ-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'CC(=O)Nc1cccc(c1)n1c(=O)n(C2CC2)c(=O)c2c1c(C)c(=O)n(c2Nc1ccc(cc1F)I)C',\n",
      "        'iupacName': 'N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide',\n",
      "        'label': 'trametinib',\n",
      "        'ligandName': 'trametinib',\n",
      "        'synonym': 'trametinib dimethyl sulfoxide',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6495'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81062'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81062'},\n",
      "         'hasLigand',\n",
      "         {'approved': 't',\n",
      "          'canonicalSMILES': 'CC(=O)Nc1cccc(c1)n1c(=O)n(C2CC2)c(=O)c2c1c(C)c(=O)n(c2Nc1ccc(cc1F)I)C',\n",
      "          'comment': 'Trametinib is a Type-3 kinase inhibitor. Marketed '\n",
      "                     'formulations contain trametinib dimethyl sulfoxide '\n",
      "                     '(PubChem <a '\n",
      "                     'href=%22https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=50992434%22>CID '\n",
      "                     '50992434</a>).',\n",
      "          'inChI': 'InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)',\n",
      "          'inChIKey': 'LIRYPHYGHXZJBZ-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'CC(=O)Nc1cccc(c1)n1c(=O)n(C2CC2)c(=O)c2c1c(C)c(=O)n(c2Nc1ccc(cc1F)I)C',\n",
      "          'iupacName': 'N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide',\n",
      "          'label': 'trametinib',\n",
      "          'ligandName': 'trametinib',\n",
      "          'synonym': 'trametinib dimethyl sulfoxide',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6495'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction86901'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'OC1CC(N(C1)C(=O)C(C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)C(=O)NC(c1ccc(cc1)c1scnc1C)C',\n",
      "        'comment': 'MS432 is the first-reported mitogen-activated protein '\n",
      "                   'kinase kinase 1/2 (MEK1/2) degrader <Reference id=38503/>. '\n",
      "                   'Structurally MS432 is a hybrid molecule, combining a '\n",
      "                   'kinase-targeting ligand (based on <Ligand id=7935/>) with '\n",
      "                   'a VHL-engaging moeity In this case VHL ligand 2, '\n",
      "                   '(<i>S,R,S</i>)-AHPC-Me  . These types of agents are known '\n",
      "                   'as PROTACs, or proteolysis targeting chimeras. It targets '\n",
      "                   'the kinases for VHL E3 ligase- and proteasome-mediated '\n",
      "                   'degradation. <i>In vitro</i>, the effect of MS432 is '\n",
      "                   'phenocopied by MEK1/2 knockdown. MS432 is bioavailable and '\n",
      "                   'suitable for <i>in vivo</i> studies.',\n",
      "        'inChI': 'InChI=1S/C50H65F3IN7O6S/c1-31(33-16-18-34(19-17-33)45-32(2)56-30-68-45)57-48(65)41-28-36(62)29-61(41)49(66)46(50(3,4)5)59-42(63)15-12-10-8-6-7-9-11-13-24-55-25-14-26-67-60-47(64)37-21-22-38(51)43(53)44(37)58-40-23-20-35(54)27-39(40)52/h16-23,27,30-31,36,41,46,55,58,62H,6-15,24-26,28-29H2,1-5H3,(H,57,65)(H,59,63)(H,60,64)/t31-,36+,41-,46+/m0/s1',\n",
      "        'inChIKey': 'KCBAMQOKOLXLOX-BSZYMOERSA-N',\n",
      "        'isomericSMILES': 'O[C@@H]1C[C@H](N(C1)C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)C(=O)N[C@H](c1ccc(cc1)c1scnc1C)C',\n",
      "        'iupacName': '(2S,4R)-1-((S)-20-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide',\n",
      "        'label': 'MS432',\n",
      "        'ligandName': 'MS432',\n",
      "        'synonym': 'compound 23 [PMID: 31730343]',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand10563'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction86901'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction86901'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'OC1CC(N(C1)C(=O)C(C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)C(=O)NC(c1ccc(cc1)c1scnc1C)C',\n",
      "          'comment': 'MS432 is the first-reported mitogen-activated protein '\n",
      "                     'kinase kinase 1/2 (MEK1/2) degrader <Reference '\n",
      "                     'id=38503/>. Structurally MS432 is a hybrid molecule, '\n",
      "                     'combining a kinase-targeting ligand (based on <Ligand '\n",
      "                     'id=7935/>) with a VHL-engaging moeity In this case VHL '\n",
      "                     'ligand 2, (<i>S,R,S</i>)-AHPC-Me  . These types of '\n",
      "                     'agents are known as PROTACs, or proteolysis targeting '\n",
      "                     'chimeras. It targets the kinases for VHL E3 ligase- and '\n",
      "                     'proteasome-mediated degradation. <i>In vitro</i>, the '\n",
      "                     'effect of MS432 is phenocopied by MEK1/2 knockdown. '\n",
      "                     'MS432 is bioavailable and suitable for <i>in vivo</i> '\n",
      "                     'studies.',\n",
      "          'inChI': 'InChI=1S/C50H65F3IN7O6S/c1-31(33-16-18-34(19-17-33)45-32(2)56-30-68-45)57-48(65)41-28-36(62)29-61(41)49(66)46(50(3,4)5)59-42(63)15-12-10-8-6-7-9-11-13-24-55-25-14-26-67-60-47(64)37-21-22-38(51)43(53)44(37)58-40-23-20-35(54)27-39(40)52/h16-23,27,30-31,36,41,46,55,58,62H,6-15,24-26,28-29H2,1-5H3,(H,57,65)(H,59,63)(H,60,64)/t31-,36+,41-,46+/m0/s1',\n",
      "          'inChIKey': 'KCBAMQOKOLXLOX-BSZYMOERSA-N',\n",
      "          'isomericSMILES': 'O[C@@H]1C[C@H](N(C1)C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)C(=O)N[C@H](c1ccc(cc1)c1scnc1C)C',\n",
      "          'iupacName': '(2S,4R)-1-((S)-20-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide',\n",
      "          'label': 'MS432',\n",
      "          'ligandName': 'MS432',\n",
      "          'synonym': 'compound 23 [PMID: 31730343]',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand10563'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85152'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'OCC1N(C)CCC1c1c(O)cc(c2c1oc(cc2=O)c1ccc(cc1Cl)C(F)(F)F)O',\n",
      "        'comment': 'Voruciclib (P1446A, or P1446A-05) is an orally active, '\n",
      "                   'non-selective CDK inhibitor that was developed for '\n",
      "                   'antineoplastic potential. Potent inhibition of CDK9, 4/6 '\n",
      "                   'and 1 by voruciclib is considered as a novel pro-apoptotic '\n",
      "                   'mechanism applicable to the treatment of malignant '\n",
      "                   'melanoma <Reference id=34919/> and to overcome resistance '\n",
      "                   'to Bcl-2 inhibition (<i>e.g.</i> by <Ligand id=8318/>) in '\n",
      "                   'B cell malignancies <Reference id=34920/><Reference '\n",
      "                   'id=34921/>.<br>Use of voruciclib in combination with BRAF '\n",
      "                   'inhibitors for the treatment of malignant melanoma is '\n",
      "                   'claimed in patent US20160136132A1 <Reference id=34922/>. '\n",
      "                   'Preparation of pure (+)-trans enantiomer of the compound '\n",
      "                   'shown here, is claimed in patent WO2007148158A1 <Reference '\n",
      "                   'id=34923/>.',\n",
      "        'inChI': 'InChI=1S/C22H19ClF3NO5/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3/t12-,14+/m1/s1',\n",
      "        'inChIKey': 'MRPGRAKIAJJGMM-OCCSQVGLSA-N',\n",
      "        'isomericSMILES': 'OC[C@@H]1N(C)CC[C@H]1c1c(O)cc(c2c1oc(cc2=O)c1ccc(cc1Cl)C(F)(F)F)O',\n",
      "        'iupacName': '2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one',\n",
      "        'label': 'voruciclib',\n",
      "        'ligandName': 'voruciclib',\n",
      "        'synonym': 'P1446A-05',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9923'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85152'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85152'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'OCC1N(C)CCC1c1c(O)cc(c2c1oc(cc2=O)c1ccc(cc1Cl)C(F)(F)F)O',\n",
      "          'comment': 'Voruciclib (P1446A, or P1446A-05) is an orally active, '\n",
      "                     'non-selective CDK inhibitor that was developed for '\n",
      "                     'antineoplastic potential. Potent inhibition of CDK9, 4/6 '\n",
      "                     'and 1 by voruciclib is considered as a novel '\n",
      "                     'pro-apoptotic mechanism applicable to the treatment of '\n",
      "                     'malignant melanoma <Reference id=34919/> and to overcome '\n",
      "                     'resistance to Bcl-2 inhibition (<i>e.g.</i> by <Ligand '\n",
      "                     'id=8318/>) in B cell malignancies <Reference '\n",
      "                     'id=34920/><Reference id=34921/>.<br>Use of voruciclib in '\n",
      "                     'combination with BRAF inhibitors for the treatment of '\n",
      "                     'malignant melanoma is claimed in patent US20160136132A1 '\n",
      "                     '<Reference id=34922/>. Preparation of pure (+)-trans '\n",
      "                     'enantiomer of the compound shown here, is claimed in '\n",
      "                     'patent WO2007148158A1 <Reference id=34923/>.',\n",
      "          'inChI': 'InChI=1S/C22H19ClF3NO5/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3/t12-,14+/m1/s1',\n",
      "          'inChIKey': 'MRPGRAKIAJJGMM-OCCSQVGLSA-N',\n",
      "          'isomericSMILES': 'OC[C@@H]1N(C)CC[C@H]1c1c(O)cc(c2c1oc(cc2=O)c1ccc(cc1Cl)C(F)(F)F)O',\n",
      "          'iupacName': '2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one',\n",
      "          'label': 'voruciclib',\n",
      "          'ligandName': 'voruciclib',\n",
      "          'synonym': 'P1446A-05',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9923'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction82791'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'N#CC(=C(Sc1ccccc1N)N)c1cccc(c1)C(c1ccncc1)O',\n",
      "        'comment': 'This is compound 41 in <Reference id=25918/>.',\n",
      "        'inChI': 'InChI=1S/C21H18N4OS/c22-13-17(21(24)27-19-7-2-1-6-18(19)23)15-4-3-5-16(12-15)20(26)14-8-10-25-11-9-14/h1-12,20,26H,23-24H2/b21-17+',\n",
      "        'inChIKey': 'NHBMKTBZZSJUGA-HEHNFIMWSA-N',\n",
      "        'isomericSMILES': 'N#C/C(=C(/Sc1ccccc1N)/N)/c1cccc(c1)C(c1ccncc1)O',\n",
      "        'iupacName': '(2Z)-3-amino-3-[(2-aminophenyl)sulfanyl]-2-{3-[hydroxy(pyridin-4-yl)methyl]phenyl}prop-2-enenitrile',\n",
      "        'label': 'MEK inhibitor I',\n",
      "        'ligandName': 'MEK inhibitor I',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6006'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 4',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 4',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2065'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction82791'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 4',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 4',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2065'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction82791'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'N#CC(=C(Sc1ccccc1N)N)c1cccc(c1)C(c1ccncc1)O',\n",
      "          'comment': 'This is compound 41 in <Reference id=25918/>.',\n",
      "          'inChI': 'InChI=1S/C21H18N4OS/c22-13-17(21(24)27-19-7-2-1-6-18(19)23)15-4-3-5-16(12-15)20(26)14-8-10-25-11-9-14/h1-12,20,26H,23-24H2/b21-17+',\n",
      "          'inChIKey': 'NHBMKTBZZSJUGA-HEHNFIMWSA-N',\n",
      "          'isomericSMILES': 'N#C/C(=C(/Sc1ccccc1N)/N)/c1cccc(c1)C(c1ccncc1)O',\n",
      "          'iupacName': '(2Z)-3-amino-3-[(2-aminophenyl)sulfanyl]-2-{3-[hydroxy(pyridin-4-yl)methyl]phenyl}prop-2-enenitrile',\n",
      "          'label': 'MEK inhibitor I',\n",
      "          'ligandName': 'MEK inhibitor I',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand6006'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 4',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 4',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2065'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85269'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'N#Cc1ccnc(c1)Nc1cc(n(n1)C1CCCC1)C1CCN(CC1)C1COC1',\n",
      "        'comment': 'Compound 11 is a potent, selective, and brain penetrant '\n",
      "                   'inhibitor of dual leucine zipper kinase (DLK, '\n",
      "                   '<i>MAP3K12</i>) <Reference id=35254/>. DLK inhibitors are '\n",
      "                   'being investigated for neuroprotective potential.',\n",
      "        'inChI': 'InChI=1S/C22H28N6O/c23-13-16-5-8-24-21(11-16)25-22-12-20(28(26-22)18-3-1-2-4-18)17-6-9-27(10-7-17)19-14-29-15-19/h5,8,11-12,17-19H,1-4,6-7,9-10,14-15H2,(H,24,25,26)',\n",
      "        'inChIKey': 'GMTAOJMPNXLKJI-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'N#Cc1ccnc(c1)Nc1cc(n(n1)C1CCCC1)C1CCN(CC1)C1COC1',\n",
      "        'iupacName': '2-[[1-cyclopentyl-5-[1-(oxetan-3-yl)piperidin-4-yl]pyrazol-3-yl]amino]pyridine-4-carbonitrile',\n",
      "        'label': 'compound 11 [PMID: 26431428]',\n",
      "        'ligandName': 'compound 11 [PMID: 26431428]',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9989'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 4',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 4',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2065'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85269'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 4',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 4',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2065'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85269'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'N#Cc1ccnc(c1)Nc1cc(n(n1)C1CCCC1)C1CCN(CC1)C1COC1',\n",
      "          'comment': 'Compound 11 is a potent, selective, and brain penetrant '\n",
      "                     'inhibitor of dual leucine zipper kinase (DLK, '\n",
      "                     '<i>MAP3K12</i>) <Reference id=35254/>. DLK inhibitors '\n",
      "                     'are being investigated for neuroprotective potential.',\n",
      "          'inChI': 'InChI=1S/C22H28N6O/c23-13-16-5-8-24-21(11-16)25-22-12-20(28(26-22)18-3-1-2-4-18)17-6-9-27(10-7-17)19-14-29-15-19/h5,8,11-12,17-19H,1-4,6-7,9-10,14-15H2,(H,24,25,26)',\n",
      "          'inChIKey': 'GMTAOJMPNXLKJI-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'N#Cc1ccnc(c1)Nc1cc(n(n1)C1CCCC1)C1CCN(CC1)C1COC1',\n",
      "          'iupacName': '2-[[1-cyclopentyl-5-[1-(oxetan-3-yl)piperidin-4-yl]pyrazol-3-yl]amino]pyridine-4-carbonitrile',\n",
      "          'label': 'compound 11 [PMID: 26431428]',\n",
      "          'ligandName': 'compound 11 [PMID: 26431428]',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9989'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 4',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 4',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2065'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81120'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'CN(Cc1cccc(c1)NC(=C1C(=O)Nc2c1ccc(c2)C(=O)N)c1ccccc1)C',\n",
      "        'comment': 'BIX02188 is an investigational inhibitor of  the STE7 '\n",
      "                   'family kinase, mitogen-activated protein kinase kinase 5 '\n",
      "                   '(MAP2K5) <Reference id=26633/>. This compound can be used '\n",
      "                   'as a pharmacological tool to help elucidate the role of '\n",
      "                   'the MEK5/ERK5 pathway in biological systems. BIX02188 is a '\n",
      "                   'closely related, marginally less potent, analogue of '\n",
      "                   '<Ligand id=9380/>. Both compounds have a similar '\n",
      "                   'selectivity profile. BIX02188 was tested in preclinical '\n",
      "                   'studies.',\n",
      "        'inChI': 'InChI=1S/C25H24N4O2/c1-29(2)15-16-7-6-10-19(13-16)27-23(17-8-4-3-5-9-17)22-20-12-11-18(24(26)30)14-21(20)28-25(22)31/h3-14,27H,15H2,1-2H3,(H2,26,30)(H,28,31)/b23-22-',\n",
      "        'inChIKey': 'FSZPIAXLCCQFCM-FCQUAONHSA-N',\n",
      "        'isomericSMILES': 'CN(Cc1cccc(c1)N/C(=C/1/C(=O)Nc2c1ccc(c2)C(=O)N)/c1ccccc1)C',\n",
      "        'iupacName': '(3Z)-3-[[3-[(dimethylamino)methyl]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxamide',\n",
      "        'label': 'BIX02188',\n",
      "        'ligandName': 'BIX02188',\n",
      "        'synonym': 'BIX 02188',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand8064'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 5',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 5',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2066'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81120'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 5',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 5',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2066'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81120'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'CN(Cc1cccc(c1)NC(=C1C(=O)Nc2c1ccc(c2)C(=O)N)c1ccccc1)C',\n",
      "          'comment': 'BIX02188 is an investigational inhibitor of  the STE7 '\n",
      "                     'family kinase, mitogen-activated protein kinase kinase 5 '\n",
      "                     '(MAP2K5) <Reference id=26633/>. This compound can be '\n",
      "                     'used as a pharmacological tool to help elucidate the '\n",
      "                     'role of the MEK5/ERK5 pathway in biological systems. '\n",
      "                     'BIX02188 is a closely related, marginally less potent, '\n",
      "                     'analogue of <Ligand id=9380/>. Both compounds have a '\n",
      "                     'similar selectivity profile. BIX02188 was tested in '\n",
      "                     'preclinical studies.',\n",
      "          'inChI': 'InChI=1S/C25H24N4O2/c1-29(2)15-16-7-6-10-19(13-16)27-23(17-8-4-3-5-9-17)22-20-12-11-18(24(26)30)14-21(20)28-25(22)31/h3-14,27H,15H2,1-2H3,(H2,26,30)(H,28,31)/b23-22-',\n",
      "          'inChIKey': 'FSZPIAXLCCQFCM-FCQUAONHSA-N',\n",
      "          'isomericSMILES': 'CN(Cc1cccc(c1)N/C(=C/1/C(=O)Nc2c1ccc(c2)C(=O)N)/c1ccccc1)C',\n",
      "          'iupacName': '(3Z)-3-[[3-[(dimethylamino)methyl]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxamide',\n",
      "          'label': 'BIX02188',\n",
      "          'ligandName': 'BIX02188',\n",
      "          'synonym': 'BIX 02188',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand8064'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 5',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 5',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2066'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83985'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'CN(Cc1cccc(c1)NC(=C1C(=O)Nc2c1ccc(c2)C(=O)N(C)C)c1ccccc1)C',\n",
      "        'comment': 'BIX02189 is an experimental, small molecule inhibitor of '\n",
      "                   'mitogen-activated protein kinase kinase 5 (MEK5; '\n",
      "                   '<i>MAP2K5</i>) <Reference id=26633/>. It is more potent '\n",
      "                   'than <Ligand id=8064/>, described in the same article. '\n",
      "                   'Also inhibits ERK5 (MAPK7).',\n",
      "        'inChI': 'InChI=1S/C27H28N4O2/c1-30(2)17-18-9-8-12-21(15-18)28-25(19-10-6-5-7-11-19)24-22-14-13-20(27(33)31(3)4)16-23(22)29-26(24)32/h5-16,28H,17H2,1-4H3,(H,29,32)/b25-24-',\n",
      "        'inChIKey': 'HOMJAAIVTDVQJA-IZHYLOQSSA-N',\n",
      "        'isomericSMILES': 'CN(Cc1cccc(c1)N/C(=C/1/C(=O)Nc2c1ccc(c2)C(=O)N(C)C)/c1ccccc1)C',\n",
      "        'iupacName': '(3Z)-3-[[3-[(dimethylamino)methyl]anilino]-phenylmethylidene]-N,N-dimethyl-2-oxo-1H-indole-6-carboxamide',\n",
      "        'label': 'BIX02189',\n",
      "        'ligandName': 'BIX02189',\n",
      "        'synonym': 'BIX-02189',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9380'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 5',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 5',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2066'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83985'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 5',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 5',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2066'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83985'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'CN(Cc1cccc(c1)NC(=C1C(=O)Nc2c1ccc(c2)C(=O)N(C)C)c1ccccc1)C',\n",
      "          'comment': 'BIX02189 is an experimental, small molecule inhibitor of '\n",
      "                     'mitogen-activated protein kinase kinase 5 (MEK5; '\n",
      "                     '<i>MAP2K5</i>) <Reference id=26633/>. It is more potent '\n",
      "                     'than <Ligand id=8064/>, described in the same article. '\n",
      "                     'Also inhibits ERK5 (MAPK7).',\n",
      "          'inChI': 'InChI=1S/C27H28N4O2/c1-30(2)17-18-9-8-12-21(15-18)28-25(19-10-6-5-7-11-19)24-22-14-13-20(27(33)31(3)4)16-23(22)29-26(24)32/h5-16,28H,17H2,1-4H3,(H,29,32)/b25-24-',\n",
      "          'inChIKey': 'HOMJAAIVTDVQJA-IZHYLOQSSA-N',\n",
      "          'isomericSMILES': 'CN(Cc1cccc(c1)N/C(=C/1/C(=O)Nc2c1ccc(c2)C(=O)N(C)C)/c1ccccc1)C',\n",
      "          'iupacName': '(3Z)-3-[[3-[(dimethylamino)methyl]anilino]-phenylmethylidene]-N,N-dimethyl-2-oxo-1H-indole-6-carboxamide',\n",
      "          'label': 'BIX02189',\n",
      "          'ligandName': 'BIX02189',\n",
      "          'synonym': 'BIX-02189',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9380'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 5',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 5',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2066'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83120'},\n",
      "  'l': {'approved': 't',\n",
      "        'canonicalSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)C1CCCCN1',\n",
      "        'comment': 'Cobimetinib is an allosteric inhibitor of MEK '\n",
      "                   'serine/threonine protein kinases, with selectivity for '\n",
      "                   'MEK1 and MEK2 <Reference id=30152/>.<br>Note that '\n",
      "                   'cobimetinib has been erroneously referred to as cometinib '\n",
      "                   'and this has propagated in online resources- cometinib is '\n",
      "                   'not an official synonym.',\n",
      "        'inChI': 'InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1',\n",
      "        'inChIKey': 'BSMCAPRUBJMWDF-KRWDZBQOSA-N',\n",
      "        'isomericSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)[C@@H]1CCCCN1',\n",
      "        'iupacName': '[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone',\n",
      "        'label': 'cobimetinib',\n",
      "        'ligandName': 'cobimetinib',\n",
      "        'synonym': 'cobimetinib fumarate',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7626'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 7',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 7',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2068'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83120'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 7',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 7',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2068'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83120'},\n",
      "         'hasLigand',\n",
      "         {'approved': 't',\n",
      "          'canonicalSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)C1CCCCN1',\n",
      "          'comment': 'Cobimetinib is an allosteric inhibitor of MEK '\n",
      "                     'serine/threonine protein kinases, with selectivity for '\n",
      "                     'MEK1 and MEK2 <Reference id=30152/>.<br>Note that '\n",
      "                     'cobimetinib has been erroneously referred to as '\n",
      "                     'cometinib and this has propagated in online resources- '\n",
      "                     'cometinib is not an official synonym.',\n",
      "          'inChI': 'InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1',\n",
      "          'inChIKey': 'BSMCAPRUBJMWDF-KRWDZBQOSA-N',\n",
      "          'isomericSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)[C@@H]1CCCCN1',\n",
      "          'iupacName': '[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone',\n",
      "          'label': 'cobimetinib',\n",
      "          'ligandName': 'cobimetinib',\n",
      "          'synonym': 'cobimetinib fumarate',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7626'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 7',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 7',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2068'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80157'},\n",
      "  'l': {'approved': 't',\n",
      "        'canonicalSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1Cl)Br)F',\n",
      "        'comment': 'Selumetinib is a selective, orally bioavailable MEK1/2 '\n",
      "                   'inhibitor <Reference id=26764/>.',\n",
      "        'inChI': 'InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)',\n",
      "        'inChIKey': 'CYOHGALHFOKKQC-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1Cl)Br)F',\n",
      "        'iupacName': '5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide',\n",
      "        'label': 'selumetinib',\n",
      "        'ligandName': 'selumetinib',\n",
      "        'synonym': 'AZD 6244',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand5665'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80157'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80157'},\n",
      "         'hasLigand',\n",
      "         {'approved': 't',\n",
      "          'canonicalSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1Cl)Br)F',\n",
      "          'comment': 'Selumetinib is a selective, orally bioavailable MEK1/2 '\n",
      "                     'inhibitor <Reference id=26764/>.',\n",
      "          'inChI': 'InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)',\n",
      "          'inChIKey': 'CYOHGALHFOKKQC-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1Cl)Br)F',\n",
      "          'iupacName': '5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide',\n",
      "          'label': 'selumetinib',\n",
      "          'ligandName': 'selumetinib',\n",
      "          'synonym': 'AZD 6244',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand5665'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80813'},\n",
      "  'l': {'approved': 't',\n",
      "        'canonicalSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1F)Br)F',\n",
      "        'comment': 'Binimetinib is a potent non-ATP competitive inhibitor of '\n",
      "                   'MEK1/2 kinase activity <Reference id=26201/> (link '\n",
      "                   'directly to abstract 794 online <a '\n",
      "                   'href=%22https://acr.confex.com/acr/2006/webprogram/Paper5558.html%22>here</a>).',\n",
      "        'inChI': 'InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)',\n",
      "        'inChIKey': 'ACWZRVQXLIRSDF-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1F)Br)F',\n",
      "        'iupacName': '6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide',\n",
      "        'label': 'binimetinib',\n",
      "        'ligandName': 'binimetinib',\n",
      "        'synonym': 'Mektovi&reg;',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7921'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80813'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80813'},\n",
      "         'hasLigand',\n",
      "         {'approved': 't',\n",
      "          'canonicalSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1F)Br)F',\n",
      "          'comment': 'Binimetinib is a potent non-ATP competitive inhibitor of '\n",
      "                     'MEK1/2 kinase activity <Reference id=26201/> (link '\n",
      "                     'directly to abstract 794 online <a '\n",
      "                     'href=%22https://acr.confex.com/acr/2006/webprogram/Paper5558.html%22>here</a>).',\n",
      "          'inChI': 'InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)',\n",
      "          'inChIKey': 'ACWZRVQXLIRSDF-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1F)Br)F',\n",
      "          'iupacName': '6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide',\n",
      "          'label': 'binimetinib',\n",
      "          'ligandName': 'binimetinib',\n",
      "          'synonym': 'Mektovi&reg;',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7921'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80845'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'OCC(CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "        'comment': 'Refametinib (BAY-869766) is a potent and selective, '\n",
      "                   'allosteric inhibitor of MEK1/2 with potential '\n",
      "                   'antineoplastic activity <Reference id=26268/>. This '\n",
      "                   \"compound is available <i>via</i> AstraZeneca's <a \"\n",
      "                   'href=%22https://openinnovation.astrazeneca.com/Refametinib-RDEA119.html%22 '\n",
      "                   'target=%22_blank%22>openinnovation</a> toolbox resource, '\n",
      "                   'which indicates that refametinib is associated with a risk '\n",
      "                   'of fetal toxicity.',\n",
      "        'inChI': 'InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1',\n",
      "        'inChIKey': 'RDSACQWTXKSHJT-NSHDSACASA-N',\n",
      "        'isomericSMILES': 'OC[C@H](CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "        'iupacName': 'N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide',\n",
      "        'label': 'refametinib',\n",
      "        'ligandName': 'refametinib',\n",
      "        'synonym': 'BAY 869766',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7942'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80845'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80845'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'OCC(CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "          'comment': 'Refametinib (BAY-869766) is a potent and selective, '\n",
      "                     'allosteric inhibitor of MEK1/2 with potential '\n",
      "                     'antineoplastic activity <Reference id=26268/>. This '\n",
      "                     \"compound is available <i>via</i> AstraZeneca's <a \"\n",
      "                     'href=%22https://openinnovation.astrazeneca.com/Refametinib-RDEA119.html%22 '\n",
      "                     'target=%22_blank%22>openinnovation</a> toolbox resource, '\n",
      "                     'which indicates that refametinib is associated with a '\n",
      "                     'risk of fetal toxicity.',\n",
      "          'inChI': 'InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1',\n",
      "          'inChIKey': 'RDSACQWTXKSHJT-NSHDSACASA-N',\n",
      "          'isomericSMILES': 'OC[C@H](CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "          'iupacName': 'N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide',\n",
      "          'label': 'refametinib',\n",
      "          'ligandName': 'refametinib',\n",
      "          'synonym': 'BAY 869766',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7942'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81289'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'Ic1ccc(c(c1)Cl)Nc1c(ccc(c1F)F)C(=O)NOCC1CC1',\n",
      "        'comment': 'CI-1040 is an investigational MEK1/2 inhibitor <Reference '\n",
      "                   'id=16562/>, which acts as a negative allosteric modulator '\n",
      "                   'of kinase activity.',\n",
      "        'inChI': 'InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)',\n",
      "        'inChIKey': 'GFMMXOIFOQCCGU-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'Ic1ccc(c(c1)Cl)Nc1c(ccc(c1F)F)C(=O)NOCC1CC1',\n",
      "        'iupacName': '2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluorobenzamide',\n",
      "        'label': 'CI-1040',\n",
      "        'ligandName': 'CI-1040',\n",
      "        'synonym': 'CI 1040',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand5676'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81289'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81289'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'Ic1ccc(c(c1)Cl)Nc1c(ccc(c1F)F)C(=O)NOCC1CC1',\n",
      "          'comment': 'CI-1040 is an investigational MEK1/2 inhibitor '\n",
      "                     '<Reference id=16562/>, which acts as a negative '\n",
      "                     'allosteric modulator of kinase activity.',\n",
      "          'inChI': 'InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)',\n",
      "          'inChIKey': 'GFMMXOIFOQCCGU-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'Ic1ccc(c(c1)Cl)Nc1c(ccc(c1F)F)C(=O)NOCC1CC1',\n",
      "          'iupacName': '2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluorobenzamide',\n",
      "          'label': 'CI-1040',\n",
      "          'ligandName': 'CI-1040',\n",
      "          'synonym': 'CI 1040',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand5676'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81290'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'Ic1ccc(c(c1)Cl)Nc1c(ccc(c1F)F)C(=O)NOCC1CC1',\n",
      "        'comment': 'CI-1040 is an investigational MEK1/2 inhibitor <Reference '\n",
      "                   'id=16562/>, which acts as a negative allosteric modulator '\n",
      "                   'of kinase activity.',\n",
      "        'inChI': 'InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)',\n",
      "        'inChIKey': 'GFMMXOIFOQCCGU-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'Ic1ccc(c(c1)Cl)Nc1c(ccc(c1F)F)C(=O)NOCC1CC1',\n",
      "        'iupacName': '2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluorobenzamide',\n",
      "        'label': 'CI-1040',\n",
      "        'ligandName': 'CI-1040',\n",
      "        'synonym': 'CI 1040',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand5676'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81290'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81290'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'Ic1ccc(c(c1)Cl)Nc1c(ccc(c1F)F)C(=O)NOCC1CC1',\n",
      "          'comment': 'CI-1040 is an investigational MEK1/2 inhibitor '\n",
      "                     '<Reference id=16562/>, which acts as a negative '\n",
      "                     'allosteric modulator of kinase activity.',\n",
      "          'inChI': 'InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)',\n",
      "          'inChIKey': 'GFMMXOIFOQCCGU-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'Ic1ccc(c(c1)Cl)Nc1c(ccc(c1F)F)C(=O)NOCC1CC1',\n",
      "          'iupacName': '2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluorobenzamide',\n",
      "          'label': 'CI-1040',\n",
      "          'ligandName': 'CI-1040',\n",
      "          'synonym': 'CI 1040',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand5676'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction86975'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'O=C(CCc1ccc(cc1)S(=O)(=O)Nc1cc(C)c(=O)n(c1Nc1ccc(cc1F)I)C)NCCOCCOCCOCC(=O)NC(C(C)(C)C)C(=O)N1CC(CC1C(=O)NC(c1ccc(cc1)c1scnc1C)C)O',\n",
      "        'comment': 'Compound 3 is a PROTAC (proteolysis targeting chimera). It '\n",
      "                   'is a hybrid molecule that simultaneously inhibits MEK '\n",
      "                   'kinase activity and recruits E3 ligase <i>via</i> a Von '\n",
      "                   'Hippel-Lindau ligand to promote proteasomal degradation of '\n",
      "                   'MEK protein <Reference id=38601/>. The kinase inhibitor '\n",
      "                   'component of the molecule is an analogue of the allosteric '\n",
      "                   'MEK inhibitor <Ligand id=7942/>.',\n",
      "        'inChI': 'InChI=1S/C53H66FIN8O11S2/c1-32-26-43(49(62(7)51(32)68)59-42-18-15-38(55)27-41(42)54)61-76(70,71)40-16-8-35(9-17-40)10-19-45(65)56-20-21-72-22-23-73-24-25-74-30-46(66)60-48(53(4,5)6)52(69)63-29-39(64)28-44(63)50(67)58-33(2)36-11-13-37(14-12-36)47-34(3)57-31-75-47/h8-9,11-18,26-27,31,33,39,44,48,59,61,64H,10,19-25,28-30H2,1-7H3,(H,56,65)(H,58,67)(H,60,66)/t33-,39+,44-,48+/m0/s1',\n",
      "        'inChIKey': 'RQBUNBWHIATPNI-WQWWALRQSA-N',\n",
      "        'isomericSMILES': 'O=C(CCc1ccc(cc1)S(=O)(=O)Nc1cc(C)c(=O)n(c1Nc1ccc(cc1F)I)C)NCCOCCOCCOCC(=O)N[C@@H](C(C)(C)C)C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@H](c1ccc(cc1)c1scnc1C)C)O',\n",
      "        'label': 'compound 3 [PMID: 31804822]',\n",
      "        'ligandName': 'compound 3 [PMID: 31804822]',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand10606'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction86975'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction86975'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'O=C(CCc1ccc(cc1)S(=O)(=O)Nc1cc(C)c(=O)n(c1Nc1ccc(cc1F)I)C)NCCOCCOCCOCC(=O)NC(C(C)(C)C)C(=O)N1CC(CC1C(=O)NC(c1ccc(cc1)c1scnc1C)C)O',\n",
      "          'comment': 'Compound 3 is a PROTAC (proteolysis targeting chimera). '\n",
      "                     'It is a hybrid molecule that simultaneously inhibits MEK '\n",
      "                     'kinase activity and recruits E3 ligase <i>via</i> a Von '\n",
      "                     'Hippel-Lindau ligand to promote proteasomal degradation '\n",
      "                     'of MEK protein <Reference id=38601/>. The kinase '\n",
      "                     'inhibitor component of the molecule is an analogue of '\n",
      "                     'the allosteric MEK inhibitor <Ligand id=7942/>.',\n",
      "          'inChI': 'InChI=1S/C53H66FIN8O11S2/c1-32-26-43(49(62(7)51(32)68)59-42-18-15-38(55)27-41(42)54)61-76(70,71)40-16-8-35(9-17-40)10-19-45(65)56-20-21-72-22-23-73-24-25-74-30-46(66)60-48(53(4,5)6)52(69)63-29-39(64)28-44(63)50(67)58-33(2)36-11-13-37(14-12-36)47-34(3)57-31-75-47/h8-9,11-18,26-27,31,33,39,44,48,59,61,64H,10,19-25,28-30H2,1-7H3,(H,56,65)(H,58,67)(H,60,66)/t33-,39+,44-,48+/m0/s1',\n",
      "          'inChIKey': 'RQBUNBWHIATPNI-WQWWALRQSA-N',\n",
      "          'isomericSMILES': 'O=C(CCc1ccc(cc1)S(=O)(=O)Nc1cc(C)c(=O)n(c1Nc1ccc(cc1F)I)C)NCCOCCOCCOCC(=O)N[C@@H](C(C)(C)C)C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@H](c1ccc(cc1)c1scnc1C)C)O',\n",
      "          'label': 'compound 3 [PMID: 31804822]',\n",
      "          'ligandName': 'compound 3 [PMID: 31804822]',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand10606'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83118'},\n",
      "  'l': {'approved': 't',\n",
      "        'canonicalSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)C1CCCCN1',\n",
      "        'comment': 'Cobimetinib is an allosteric inhibitor of MEK '\n",
      "                   'serine/threonine protein kinases, with selectivity for '\n",
      "                   'MEK1 and MEK2 <Reference id=30152/>.<br>Note that '\n",
      "                   'cobimetinib has been erroneously referred to as cometinib '\n",
      "                   'and this has propagated in online resources- cometinib is '\n",
      "                   'not an official synonym.',\n",
      "        'inChI': 'InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1',\n",
      "        'inChIKey': 'BSMCAPRUBJMWDF-KRWDZBQOSA-N',\n",
      "        'isomericSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)[C@@H]1CCCCN1',\n",
      "        'iupacName': '[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone',\n",
      "        'label': 'cobimetinib',\n",
      "        'ligandName': 'cobimetinib',\n",
      "        'synonym': 'cobimetinib fumarate',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7626'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83118'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83118'},\n",
      "         'hasLigand',\n",
      "         {'approved': 't',\n",
      "          'canonicalSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)C1CCCCN1',\n",
      "          'comment': 'Cobimetinib is an allosteric inhibitor of MEK '\n",
      "                     'serine/threonine protein kinases, with selectivity for '\n",
      "                     'MEK1 and MEK2 <Reference id=30152/>.<br>Note that '\n",
      "                     'cobimetinib has been erroneously referred to as '\n",
      "                     'cometinib and this has propagated in online resources- '\n",
      "                     'cometinib is not an official synonym.',\n",
      "          'inChI': 'InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1',\n",
      "          'inChIKey': 'BSMCAPRUBJMWDF-KRWDZBQOSA-N',\n",
      "          'isomericSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)[C@@H]1CCCCN1',\n",
      "          'iupacName': '[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone',\n",
      "          'label': 'cobimetinib',\n",
      "          'ligandName': 'cobimetinib',\n",
      "          'synonym': 'cobimetinib fumarate',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7626'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85069'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'OCC(Cn1cnc2c(c1=O)c(Nc1ccc(cc1F)I)c(c(=O)n2C)F)O',\n",
      "        'comment': 'TAK-733 is a potent and selective MEK inhibitor with an '\n",
      "                   'allosteric binding mode, that was designed as a novel '\n",
      "                   'cancer chemotherapeutic <Reference id=34892/>.',\n",
      "        'inChI': 'InChI=1S/C17H15F2IN4O4/c1-23-15-12(16(27)24(7-21-15)5-9(26)6-25)14(13(19)17(23)28)22-11-3-2-8(20)4-10(11)18/h2-4,7,9,22,25-26H,5-6H2,1H3/t9-/m1/s1',\n",
      "        'inChIKey': 'RCLQNICOARASSR-SECBINFHSA-N',\n",
      "        'isomericSMILES': 'OC[C@@H](Cn1cnc2c(c1=O)c(Nc1ccc(cc1F)I)c(c(=O)n2C)F)O',\n",
      "        'iupacName': '3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione',\n",
      "        'label': 'TAK-733',\n",
      "        'ligandName': 'TAK-733',\n",
      "        'synonym': 'compound 17 [PMID: 21310613]',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9911'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85069'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction85069'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'OCC(Cn1cnc2c(c1=O)c(Nc1ccc(cc1F)I)c(c(=O)n2C)F)O',\n",
      "          'comment': 'TAK-733 is a potent and selective MEK inhibitor with an '\n",
      "                     'allosteric binding mode, that was designed as a novel '\n",
      "                     'cancer chemotherapeutic <Reference id=34892/>.',\n",
      "          'inChI': 'InChI=1S/C17H15F2IN4O4/c1-23-15-12(16(27)24(7-21-15)5-9(26)6-25)14(13(19)17(23)28)22-11-3-2-8(20)4-10(11)18/h2-4,7,9,22,25-26H,5-6H2,1H3/t9-/m1/s1',\n",
      "          'inChIKey': 'RCLQNICOARASSR-SECBINFHSA-N',\n",
      "          'isomericSMILES': 'OC[C@@H](Cn1cnc2c(c1=O)c(Nc1ccc(cc1F)I)c(c(=O)n2C)F)O',\n",
      "          'iupacName': '3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione',\n",
      "          'label': 'TAK-733',\n",
      "          'ligandName': 'TAK-733',\n",
      "          'synonym': 'compound 17 [PMID: 21310613]',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand9911'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 1',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 1',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2062'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80814'},\n",
      "  'l': {'approved': 't',\n",
      "        'canonicalSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1F)Br)F',\n",
      "        'comment': 'Binimetinib is a potent non-ATP competitive inhibitor of '\n",
      "                   'MEK1/2 kinase activity <Reference id=26201/> (link '\n",
      "                   'directly to abstract 794 online <a '\n",
      "                   'href=%22https://acr.confex.com/acr/2006/webprogram/Paper5558.html%22>here</a>).',\n",
      "        'inChI': 'InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)',\n",
      "        'inChIKey': 'ACWZRVQXLIRSDF-UHFFFAOYSA-N',\n",
      "        'isomericSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1F)Br)F',\n",
      "        'iupacName': '6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide',\n",
      "        'label': 'binimetinib',\n",
      "        'ligandName': 'binimetinib',\n",
      "        'synonym': 'Mektovi&reg;',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7921'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80814'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80814'},\n",
      "         'hasLigand',\n",
      "         {'approved': 't',\n",
      "          'canonicalSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1F)Br)F',\n",
      "          'comment': 'Binimetinib is a potent non-ATP competitive inhibitor of '\n",
      "                     'MEK1/2 kinase activity <Reference id=26201/> (link '\n",
      "                     'directly to abstract 794 online <a '\n",
      "                     'href=%22https://acr.confex.com/acr/2006/webprogram/Paper5558.html%22>here</a>).',\n",
      "          'inChI': 'InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)',\n",
      "          'inChIKey': 'ACWZRVQXLIRSDF-UHFFFAOYSA-N',\n",
      "          'isomericSMILES': 'OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1F)Br)F',\n",
      "          'iupacName': '6-[(4-bromo-2-fluorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide',\n",
      "          'label': 'binimetinib',\n",
      "          'ligandName': 'binimetinib',\n",
      "          'synonym': 'Mektovi&reg;',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7921'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80846'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'OCC(CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "        'comment': 'Refametinib (BAY-869766) is a potent and selective, '\n",
      "                   'allosteric inhibitor of MEK1/2 with potential '\n",
      "                   'antineoplastic activity <Reference id=26268/>. This '\n",
      "                   \"compound is available <i>via</i> AstraZeneca's <a \"\n",
      "                   'href=%22https://openinnovation.astrazeneca.com/Refametinib-RDEA119.html%22 '\n",
      "                   'target=%22_blank%22>openinnovation</a> toolbox resource, '\n",
      "                   'which indicates that refametinib is associated with a risk '\n",
      "                   'of fetal toxicity.',\n",
      "        'inChI': 'InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1',\n",
      "        'inChIKey': 'RDSACQWTXKSHJT-NSHDSACASA-N',\n",
      "        'isomericSMILES': 'OC[C@H](CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "        'iupacName': 'N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide',\n",
      "        'label': 'refametinib',\n",
      "        'ligandName': 'refametinib',\n",
      "        'synonym': 'BAY 869766',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7942'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80846'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80846'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'OCC(CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "          'comment': 'Refametinib (BAY-869766) is a potent and selective, '\n",
      "                     'allosteric inhibitor of MEK1/2 with potential '\n",
      "                     'antineoplastic activity <Reference id=26268/>. This '\n",
      "                     \"compound is available <i>via</i> AstraZeneca's <a \"\n",
      "                     'href=%22https://openinnovation.astrazeneca.com/Refametinib-RDEA119.html%22 '\n",
      "                     'target=%22_blank%22>openinnovation</a> toolbox resource, '\n",
      "                     'which indicates that refametinib is associated with a '\n",
      "                     'risk of fetal toxicity.',\n",
      "          'inChI': 'InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24-27H,4-5,8-9H2,1H3/t11-/m0/s1',\n",
      "          'inChIKey': 'RDSACQWTXKSHJT-NSHDSACASA-N',\n",
      "          'isomericSMILES': 'OC[C@H](CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O',\n",
      "          'iupacName': 'N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide',\n",
      "          'label': 'refametinib',\n",
      "          'ligandName': 'refametinib',\n",
      "          'synonym': 'BAY 869766',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7942'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83119'},\n",
      "  'l': {'approved': 't',\n",
      "        'canonicalSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)C1CCCCN1',\n",
      "        'comment': 'Cobimetinib is an allosteric inhibitor of MEK '\n",
      "                   'serine/threonine protein kinases, with selectivity for '\n",
      "                   'MEK1 and MEK2 <Reference id=30152/>.<br>Note that '\n",
      "                   'cobimetinib has been erroneously referred to as cometinib '\n",
      "                   'and this has propagated in online resources- cometinib is '\n",
      "                   'not an official synonym.',\n",
      "        'inChI': 'InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1',\n",
      "        'inChIKey': 'BSMCAPRUBJMWDF-KRWDZBQOSA-N',\n",
      "        'isomericSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)[C@@H]1CCCCN1',\n",
      "        'iupacName': '[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone',\n",
      "        'label': 'cobimetinib',\n",
      "        'ligandName': 'cobimetinib',\n",
      "        'synonym': 'cobimetinib fumarate',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7626'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83119'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction83119'},\n",
      "         'hasLigand',\n",
      "         {'approved': 't',\n",
      "          'canonicalSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)C1CCCCN1',\n",
      "          'comment': 'Cobimetinib is an allosteric inhibitor of MEK '\n",
      "                     'serine/threonine protein kinases, with selectivity for '\n",
      "                     'MEK1 and MEK2 <Reference id=30152/>.<br>Note that '\n",
      "                     'cobimetinib has been erroneously referred to as '\n",
      "                     'cometinib and this has propagated in online resources- '\n",
      "                     'cometinib is not an official synonym.',\n",
      "          'inChI': 'InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1',\n",
      "          'inChIKey': 'BSMCAPRUBJMWDF-KRWDZBQOSA-N',\n",
      "          'isomericSMILES': 'Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)[C@@H]1CCCCN1',\n",
      "          'iupacName': '[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone',\n",
      "          'label': 'cobimetinib',\n",
      "          'ligandName': 'cobimetinib',\n",
      "          'synonym': 'cobimetinib fumarate',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7626'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 2',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 2',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2063'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81545'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O',\n",
      "        'comment': 'Staurosporine is a non-specific, ATP-competitive inhibitor '\n",
      "                   'of protein kinase C (PKC) isolated from a '\n",
      "                   '<i>Streptomyces</i> strain <Reference id=26820/>. It '\n",
      "                   'inhibits all PKC enzyme isoforms <Reference '\n",
      "                   'id=26819/><Reference id=26821/>, but has a more potent '\n",
      "                   'inhibitory effect on PKCs associated with the cell '\n",
      "                   'membrane compared to cytosolic PKCs.<br>Staurosporine '\n",
      "                   'analogues such as <Ligand id=5702/> and <Ligand id=7907/> '\n",
      "                   'are being investigated as therapeutics.',\n",
      "        'inChI': 'InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1',\n",
      "        'inChIKey': 'HKSZLNNOFSGOKW-FYTWVXJKSA-N',\n",
      "        'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O',\n",
      "        'iupacName': '(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-16-one',\n",
      "        'label': 'staurosporine',\n",
      "        'ligandName': 'staurosporine',\n",
      "        'synonym': 'antibiotic AM-2282',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand346'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 4',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 4',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2065'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81545'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 4',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 4',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2065'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81545'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O',\n",
      "          'comment': 'Staurosporine is a non-specific, ATP-competitive '\n",
      "                     'inhibitor of protein kinase C (PKC) isolated from a '\n",
      "                     '<i>Streptomyces</i> strain <Reference id=26820/>. It '\n",
      "                     'inhibits all PKC enzyme isoforms <Reference '\n",
      "                     'id=26819/><Reference id=26821/>, but has a more potent '\n",
      "                     'inhibitory effect on PKCs associated with the cell '\n",
      "                     'membrane compared to cytosolic PKCs.<br>Staurosporine '\n",
      "                     'analogues such as <Ligand id=5702/> and <Ligand '\n",
      "                     'id=7907/> are being investigated as therapeutics.',\n",
      "          'inChI': 'InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1',\n",
      "          'inChIKey': 'HKSZLNNOFSGOKW-FYTWVXJKSA-N',\n",
      "          'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O',\n",
      "          'iupacName': '(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-16-one',\n",
      "          'label': 'staurosporine',\n",
      "          'ligandName': 'staurosporine',\n",
      "          'synonym': 'antibiotic AM-2282',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand346'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 4',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 4',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2065'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}},\n",
      " {'i': {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81546'},\n",
      "  'l': {'approved': 'f',\n",
      "        'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O',\n",
      "        'comment': 'Staurosporine is a non-specific, ATP-competitive inhibitor '\n",
      "                   'of protein kinase C (PKC) isolated from a '\n",
      "                   '<i>Streptomyces</i> strain <Reference id=26820/>. It '\n",
      "                   'inhibits all PKC enzyme isoforms <Reference '\n",
      "                   'id=26819/><Reference id=26821/>, but has a more potent '\n",
      "                   'inhibitory effect on PKCs associated with the cell '\n",
      "                   'membrane compared to cytosolic PKCs.<br>Staurosporine '\n",
      "                   'analogues such as <Ligand id=5702/> and <Ligand id=7907/> '\n",
      "                   'are being investigated as therapeutics.',\n",
      "        'inChI': 'InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1',\n",
      "        'inChIKey': 'HKSZLNNOFSGOKW-FYTWVXJKSA-N',\n",
      "        'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O',\n",
      "        'iupacName': '(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-16-one',\n",
      "        'label': 'staurosporine',\n",
      "        'ligandName': 'staurosporine',\n",
      "        'synonym': 'antibiotic AM-2282',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand346'},\n",
      "  'r1': ({'label': 'mitogen-activated protein kinase kinase 6',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 6',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2067'},\n",
      "         'hasTargetFamily',\n",
      "         {'label': 'STE7 family',\n",
      "          'targetFamilyName': 'STE7 family',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}),\n",
      "  'r2': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81546'},\n",
      "         'hasTarget',\n",
      "         {'label': 'mitogen-activated protein kinase kinase 6',\n",
      "          'nomenclature': 'mitogen-activated protein kinase kinase 6',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2067'}),\n",
      "  'r3': ({'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81546'},\n",
      "         'hasLigand',\n",
      "         {'approved': 'f',\n",
      "          'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O',\n",
      "          'comment': 'Staurosporine is a non-specific, ATP-competitive '\n",
      "                     'inhibitor of protein kinase C (PKC) isolated from a '\n",
      "                     '<i>Streptomyces</i> strain <Reference id=26820/>. It '\n",
      "                     'inhibits all PKC enzyme isoforms <Reference '\n",
      "                     'id=26819/><Reference id=26821/>, but has a more potent '\n",
      "                     'inhibitory effect on PKCs associated with the cell '\n",
      "                     'membrane compared to cytosolic PKCs.<br>Staurosporine '\n",
      "                     'analogues such as <Ligand id=5702/> and <Ligand '\n",
      "                     'id=7907/> are being investigated as therapeutics.',\n",
      "          'inChI': 'InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1',\n",
      "          'inChIKey': 'HKSZLNNOFSGOKW-FYTWVXJKSA-N',\n",
      "          'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O',\n",
      "          'iupacName': '(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-16-one',\n",
      "          'label': 'staurosporine',\n",
      "          'ligandName': 'staurosporine',\n",
      "          'synonym': 'antibiotic AM-2282',\n",
      "          'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand346'}),\n",
      "  't': {'label': 'mitogen-activated protein kinase kinase 6',\n",
      "        'nomenclature': 'mitogen-activated protein kinase kinase 6',\n",
      "        'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2067'},\n",
      "  'tf': {'label': 'STE7 family',\n",
      "         'targetFamilyName': 'STE7 family',\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily623'}}]\n"
     ]
    }
   ],
   "source": [
    "from pprint import pprint\n",
    "\n",
    "# Execute the query and display the results\n",
    "results = run_cypher_query(cypher_query)\n",
    "pprint(results)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "0Ls7Mu6ZSfK5"
   },
   "source": [
    "This query retrieves information about the STE7 target family, including related targets, interactions, and ligands."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Querying for a list of drug compounds"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "cypher_query = \"\"\"\n",
    "MATCH (l:Resource)\n",
    "WHERE l.ligandName IN ['5-nitroso-8-quinolinol', '7-hydroxystaurosporine', 'alisertib', 'AMG 900', 'AR-42',\n",
    "    'AT7519', 'AZD1152-HQPA', 'AZD5438', 'belinostat', 'Bms-265246', 'CCT129202', 'CCT137690',\n",
    "    'CYC116', 'dinaciclib', 'ENMD-2076', 'entinostat', 'flavopiridol', 'indisulam', 'M 344',\n",
    "    'nexturastat A', 'panobinostat', 'PF-03814735', 'PHA-793887', 'pyroxamide', 'R-547',\n",
    "    'R306465', 'resminostat', 'RGFP966', 'ricolinostat', 'riviciclib', 'SB1317/TG02', 'Sns-032',\n",
    "    'SNS-314 mesylate', 'tozasertib', 'ZM-447439']\n",
    "MATCH path = (l)-[:hasLigand]-(i)-[:hasTarget]-(t)-[:hasTargetFamily]-(tf)\n",
    "    OPTIONAL MATCH (i)-[:hasAction]-(a)\n",
    "    OPTIONAL MATCH (i)-[:hasAffinity]-(af)\n",
    "    OPTIONAL MATCH (i)-[:hasReference]-(r)\n",
    "    OPTIONAL MATCH (l)-[:xref]-(xr)\n",
    "RETURN path, a, af, r\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Execute the query and display the results\n",
    "results = run_cypher_query(cypher_query)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[{'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.570000171661377,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80785'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80785'},\n",
      "           'hasTarget',\n",
      "           {'label': 'microtubule affinity regulating kinase 1',\n",
      "            'nomenclature': 'microtubule affinity regulating kinase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2097'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'MARK subfamily',\n",
      "            'targetFamilyName': 'MARK subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily479'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/10786669'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasHighValue': 8.149999618530273,\n",
      "         'hasLowValue': 7.460000038146973,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80779'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80779'},\n",
      "           'hasTarget',\n",
      "           {'label': 'checkpoint kinase 1',\n",
      "            'nomenclature': 'checkpoint kinase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1987'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CHK1 subfamily',\n",
      "            'targetFamilyName': 'CHK1 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily476'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/10786669'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasHighValue': 8.149999618530273,\n",
      "         'hasLowValue': 7.460000038146973,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80779'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80779'},\n",
      "           'hasTarget',\n",
      "           {'label': 'checkpoint kinase 1',\n",
      "            'nomenclature': 'checkpoint kinase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1987'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CHK1 subfamily',\n",
      "            'targetFamilyName': 'CHK1 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily476'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/15486189'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasHighValue': 8.149999618530273,\n",
      "         'hasLowValue': 7.460000038146973,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80779'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80779'},\n",
      "           'hasTarget',\n",
      "           {'label': 'checkpoint kinase 1',\n",
      "            'nomenclature': 'checkpoint kinase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1987'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CHK1 subfamily',\n",
      "            'targetFamilyName': 'CHK1 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily476'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17292828'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 9.0,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80483'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'COc1cccc(c1C1=NCc2c(c3c1cc(Cl)cc3)nc(nc2)Nc1ccc(c(c1)OC)C(=O)O)F',\n",
      "            'comment': 'Alisertib is a second generation, orally bioavailable '\n",
      "                       'and selective Aurora kinase A inhibitor.',\n",
      "            'inChI': 'InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)',\n",
      "            'inChIKey': 'ZLHFILGSQDJULK-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'COc1cccc(c1C1=NCc2c(c3c1cc(Cl)cc3)nc(nc2)Nc1ccc(c(c1)OC)C(=O)O)F',\n",
      "            'iupacName': '4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic '\n",
      "                         'acid',\n",
      "            'label': 'alisertib',\n",
      "            'ligandName': 'alisertib',\n",
      "            'synonym': 'MLN-8237',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7790'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80483'},\n",
      "           'hasTarget',\n",
      "           {'label': 'aurora kinase A',\n",
      "            'nomenclature': 'aurora kinase A',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1936'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Aurora kinase (Aur) family',\n",
      "            'targetFamilyName': 'Aurora kinase (Aur) family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily557'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/19320489'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.849999904632568,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80744'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CN1CCN(CC1)c1nc(C=Cc2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'comment': 'ENMD-2076 is an orally-active, Aurora A/angiogenic '\n",
      "                       'kinase inhibitor. It inhibits a distinct profile of '\n",
      "                       'angiogenic tyrosine kinases in addition to the Aurora '\n",
      "                       'A kinase. These angiogenic targets include VEGFR, Flt3 '\n",
      "                       'and FGFR3 kinases, which have been shown to play '\n",
      "                       'important roles in the pathology of several cancers.',\n",
      "            'inChI': 'InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+',\n",
      "            'inChIKey': 'BLQYVHBZHAISJM-CMDGGOBGSA-N',\n",
      "            'isomericSMILES': 'CN1CCN(CC1)c1nc(/C=C/c2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'iupacName': '6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine',\n",
      "            'label': 'ENMD-2076',\n",
      "            'ligandName': 'ENMD-2076',\n",
      "            'synonym': 'ENMD 2076',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7885'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80744'},\n",
      "           'hasTarget',\n",
      "           {'label': 'aurora kinase A',\n",
      "            'nomenclature': 'aurora kinase A',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1936'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Aurora kinase (Aur) family',\n",
      "            'targetFamilyName': 'Aurora kinase (Aur) family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily557'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/19320489'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.40999984741211,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity81212'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)Nc1[nH]nc(c1)C',\n",
      "            'comment': 'Tozasertib is a potent inhibitor of all three members '\n",
      "                       'of the Aurora kinase family <Reference id=26758/>.',\n",
      "            'inChI': 'InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)',\n",
      "            'inChIKey': 'GCIKSSRWRFVXBI-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)Nc1[nH]nc(c1)C',\n",
      "            'iupacName': 'N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide',\n",
      "            'label': 'tozasertib',\n",
      "            'ligandName': 'tozasertib',\n",
      "            'synonym': 'VX680',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand5718'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81212'},\n",
      "           'hasTarget',\n",
      "           {'label': 'aurora kinase A',\n",
      "            'nomenclature': 'aurora kinase A',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1936'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Aurora kinase (Aur) family',\n",
      "            'targetFamilyName': 'Aurora kinase (Aur) family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily557'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/22037378'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 9.220000267028809,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity81214'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)Nc1[nH]nc(c1)C',\n",
      "            'comment': 'Tozasertib is a potent inhibitor of all three members '\n",
      "                       'of the Aurora kinase family <Reference id=26758/>.',\n",
      "            'inChI': 'InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)',\n",
      "            'inChIKey': 'GCIKSSRWRFVXBI-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)Nc1[nH]nc(c1)C',\n",
      "            'iupacName': 'N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide',\n",
      "            'label': 'tozasertib',\n",
      "            'ligandName': 'tozasertib',\n",
      "            'synonym': 'VX680',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand5718'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81214'},\n",
      "           'hasTarget',\n",
      "           {'label': 'aurora kinase A',\n",
      "            'nomenclature': 'aurora kinase A',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1936'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Aurora kinase (Aur) family',\n",
      "            'targetFamilyName': 'Aurora kinase (Aur) family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily557'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/14981513'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.480000019073486,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80784'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80784'},\n",
      "           'hasTarget',\n",
      "           {'label': '3-phosphoinositide dependent protein kinase 1',\n",
      "            'nomenclature': '3-phosphoinositide dependent protein kinase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1519'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'PDK1 family',\n",
      "            'targetFamilyName': 'PDK1 family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily604'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/11896604'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.260000228881836,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80749'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CN1CCN(CC1)c1nc(C=Cc2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'comment': 'ENMD-2076 is an orally-active, Aurora A/angiogenic '\n",
      "                       'kinase inhibitor. It inhibits a distinct profile of '\n",
      "                       'angiogenic tyrosine kinases in addition to the Aurora '\n",
      "                       'A kinase. These angiogenic targets include VEGFR, Flt3 '\n",
      "                       'and FGFR3 kinases, which have been shown to play '\n",
      "                       'important roles in the pathology of several cancers.',\n",
      "            'inChI': 'InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+',\n",
      "            'inChIKey': 'BLQYVHBZHAISJM-CMDGGOBGSA-N',\n",
      "            'isomericSMILES': 'CN1CCN(CC1)c1nc(/C=C/c2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'iupacName': '6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine',\n",
      "            'label': 'ENMD-2076',\n",
      "            'ligandName': 'ENMD-2076',\n",
      "            'synonym': 'ENMD 2076',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7885'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80749'},\n",
      "           'hasTarget',\n",
      "           {'label': 'protein tyrosine kinase 2',\n",
      "            'nomenclature': 'protein tyrosine kinase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2180'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Fak family',\n",
      "            'targetFamilyName': 'Fak family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily574'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/19320489'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.739999771118164,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity81213'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)Nc1[nH]nc(c1)C',\n",
      "            'comment': 'Tozasertib is a potent inhibitor of all three members '\n",
      "                       'of the Aurora kinase family <Reference id=26758/>.',\n",
      "            'inChI': 'InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)',\n",
      "            'inChIKey': 'GCIKSSRWRFVXBI-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)Nc1[nH]nc(c1)C',\n",
      "            'iupacName': 'N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide',\n",
      "            'label': 'tozasertib',\n",
      "            'ligandName': 'tozasertib',\n",
      "            'synonym': 'VX680',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand5718'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81213'},\n",
      "           'hasTarget',\n",
      "           {'label': 'aurora kinase B',\n",
      "            'nomenclature': 'aurora kinase B',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1937'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Aurora kinase (Aur) family',\n",
      "            'targetFamilyName': 'Aurora kinase (Aur) family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily557'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/14981513'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.34000015258789,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity81215'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)Nc1[nH]nc(c1)C',\n",
      "            'comment': 'Tozasertib is a potent inhibitor of all three members '\n",
      "                       'of the Aurora kinase family <Reference id=26758/>.',\n",
      "            'inChI': 'InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)',\n",
      "            'inChIKey': 'GCIKSSRWRFVXBI-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)Nc1[nH]nc(c1)C',\n",
      "            'iupacName': 'N-[4-({4-[(3-methyl-1H-pyrazol-5-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide',\n",
      "            'label': 'tozasertib',\n",
      "            'ligandName': 'tozasertib',\n",
      "            'synonym': 'VX680',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand5718'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction81215'},\n",
      "           'hasTarget',\n",
      "           {'label': 'aurora kinase C',\n",
      "            'nomenclature': 'aurora kinase C',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1938'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Aurora kinase (Aur) family',\n",
      "            'targetFamilyName': 'Aurora kinase (Aur) family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily557'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/14981513'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 5.980000019073486,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80786'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80786'},\n",
      "           'hasTarget',\n",
      "           {'label': 'checkpoint kinase 2',\n",
      "            'nomenclature': 'checkpoint kinase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1988'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'RAD53 family',\n",
      "            'targetFamilyName': 'RAD53 family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily609'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/10786669'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 5.980000019073486,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80786'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80786'},\n",
      "           'hasTarget',\n",
      "           {'label': 'checkpoint kinase 2',\n",
      "            'nomenclature': 'checkpoint kinase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1988'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CHK1 subfamily',\n",
      "            'targetFamilyName': 'CHK1 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily476'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/10786669'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.519999980926514,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80788'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80788'},\n",
      "           'hasTarget',\n",
      "           {'label': 'protein kinase C gamma',\n",
      "            'nomenclature': 'protein kinase C gamma',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1484'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Alpha subfamily',\n",
      "            'targetFamilyName': 'Alpha subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily532'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/8022414'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.699999809265137,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80748'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CN1CCN(CC1)c1nc(C=Cc2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'comment': 'ENMD-2076 is an orally-active, Aurora A/angiogenic '\n",
      "                       'kinase inhibitor. It inhibits a distinct profile of '\n",
      "                       'angiogenic tyrosine kinases in addition to the Aurora '\n",
      "                       'A kinase. These angiogenic targets include VEGFR, Flt3 '\n",
      "                       'and FGFR3 kinases, which have been shown to play '\n",
      "                       'important roles in the pathology of several cancers.',\n",
      "            'inChI': 'InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+',\n",
      "            'inChIKey': 'BLQYVHBZHAISJM-CMDGGOBGSA-N',\n",
      "            'isomericSMILES': 'CN1CCN(CC1)c1nc(/C=C/c2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'iupacName': '6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine',\n",
      "            'label': 'ENMD-2076',\n",
      "            'ligandName': 'ENMD-2076',\n",
      "            'synonym': 'ENMD 2076',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7885'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80748'},\n",
      "           'hasTarget',\n",
      "           {'label': 'SRC proto-oncogene, non-receptor tyrosine kinase',\n",
      "            'nomenclature': 'SRC proto-oncogene, non-receptor tyrosine kinase',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2206'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Src family',\n",
      "            'targetFamilyName': 'Src family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily619'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/19320489'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.539999961853027,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80787'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80787'},\n",
      "           'hasTarget',\n",
      "           {'label': 'protein kinase C beta',\n",
      "            'nomenclature': 'protein kinase C beta',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1483'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Alpha subfamily',\n",
      "            'targetFamilyName': 'Alpha subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily532'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/8022414'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.300000190734863,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80782'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80782'},\n",
      "           'hasTarget',\n",
      "           {'label': 'LCK proto-oncogene, Src family tyrosine kinase',\n",
      "            'nomenclature': 'LCK proto-oncogene, Src family tyrosine kinase',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2053'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Src family',\n",
      "            'targetFamilyName': 'Src family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily619'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/15486189'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.520000457763672,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79362'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'OCCC1CCCCN1c1cc(NCc2ccc[n+](c2)[O-])n2c(n1)c(CC)cn2',\n",
      "            'comment': 'Dinaciclib is a potent cyclin-dependent kinase (CDK) '\n",
      "                       'inhibitor, inhibiting the CDK4 and 6 isoforms '\n",
      "                       '<Reference id=24187/>. Dinaciclib has also been '\n",
      "                       'reported to interact with the acetyl-lysine '\n",
      "                       'recognition domain of the bromodomain testis-specific '\n",
      "                       'protein BRDT <Reference id=24187/>. BRDT is a member '\n",
      "                       'of the BET family of bromodomain-containing proteins '\n",
      "                       'which are considered to be atypical '\n",
      "                       'kinases.<br><br><b>SARS-CoV-2: </b>SARS-CoV-2 may '\n",
      "                       'regulate the host cell cycle to enhance viral '\n",
      "                       'replication, and <i>in vitro</i> phosphoproteomics '\n",
      "                       'analysis suggests that viral hijacking of the CDK '\n",
      "                       'signalling pathway may, at least in part, mediate this '\n",
      "                       'mechanism <Reference id=39830/>. Pharmacological '\n",
      "                       'inhibition of the CDK pathway with dinaciclib has '\n",
      "                       'anti-SARS-CoV-2 activity in two model cells lines, '\n",
      "                       'A549-ACE2 cells (IC<sub>50</sub> 32 nM) and Vero E6 '\n",
      "                       'cells (IC<sub>50</sub> 127 nM).',\n",
      "            'inChI': 'InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1',\n",
      "            'inChIKey': 'PIMQWRZWLQKKBJ-SFHVURJKSA-N',\n",
      "            'isomericSMILES': 'OCC[C@@H]1CCCCN1c1cc(NCc2ccc[n+](c2)[O-])n2c(n1)c(CC)cn2',\n",
      "            'iupacName': '2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol',\n",
      "            'label': 'dinaciclib',\n",
      "            'ligandName': 'dinaciclib',\n",
      "            'synonym': 'SCH727965',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7379'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79362'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 1',\n",
      "            'nomenclature': 'cyclin dependent kinase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1961'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK1 subfamily',\n",
      "            'targetFamilyName': 'CDK1 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily492'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/24007471'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.300000190734863,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80780'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80780'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 1',\n",
      "            'nomenclature': 'cyclin dependent kinase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1961'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK1 subfamily',\n",
      "            'targetFamilyName': 'CDK1 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily492'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/15486189'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.099999904632568,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80831'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'OCC1N(C)CCC1c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O',\n",
      "            'comment': 'Riviciclib is a flavone based cyclin dependent kinase '\n",
      "                       '(CDK) inhibitor with potential antineoplastic activity '\n",
      "                       '<Reference id=26250/>.',\n",
      "            'inChI': 'InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3/t12-,14+/m1/s1',\n",
      "            'inChIKey': 'QLUYMIVVAYRECT-OCCSQVGLSA-N',\n",
      "            'isomericSMILES': 'OC[C@@H]1N(C)CC[C@H]1c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O',\n",
      "            'iupacName': '2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one',\n",
      "            'label': 'riviciclib',\n",
      "            'ligandName': 'riviciclib',\n",
      "            'synonym': 'P276-00',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7934'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80831'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 1',\n",
      "            'nomenclature': 'cyclin dependent kinase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1961'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK1 subfamily',\n",
      "            'targetFamilyName': 'CDK1 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily492'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17363486'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.800000190734863,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity82207'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CC(n1c(C)ncc1c1ccnc(n1)Nc1ccc(cc1)S(=O)(=O)C)C',\n",
      "            'comment': 'AZD5438 is a potent oral inhibitor of cyclin dependent '\n",
      "                       'kinases (CDKs) 1, 2 and 9 <Reference id=28188/>.',\n",
      "            'inChI': 'InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)',\n",
      "            'inChIKey': 'WJRRGYBTGDJBFX-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'CC(n1c(C)ncc1c1ccnc(n1)Nc1ccc(cc1)S(=O)(=O)C)C',\n",
      "            'iupacName': '4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine',\n",
      "            'label': 'AZD5438',\n",
      "            'ligandName': 'AZD5438',\n",
      "            'synonym': 'AZD-5438',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand8473'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction82207'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 1',\n",
      "            'nomenclature': 'cyclin dependent kinase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1961'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK1 subfamily',\n",
      "            'targetFamilyName': 'CDK1 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily492'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/19509270'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.230000019073486,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80790'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80790'},\n",
      "           'hasTarget',\n",
      "           {'label': 'protein kinase C delta',\n",
      "            'nomenclature': 'protein kinase C delta',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1485'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Delta subfamily',\n",
      "            'targetFamilyName': 'Delta subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily533'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/8022414'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.28000020980835,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80791'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80791'},\n",
      "           'hasTarget',\n",
      "           {'label': 'protein kinase C epsilon',\n",
      "            'nomenclature': 'protein kinase C epsilon',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1486'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Eta subfamily',\n",
      "            'targetFamilyName': 'Eta subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily534'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/8022414'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.199999809265137,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80830'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'OCC1N(C)CCC1c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O',\n",
      "            'comment': 'Riviciclib is a flavone based cyclin dependent kinase '\n",
      "                       '(CDK) inhibitor with potential antineoplastic activity '\n",
      "                       '<Reference id=26250/>.',\n",
      "            'inChI': 'InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3/t12-,14+/m1/s1',\n",
      "            'inChIKey': 'QLUYMIVVAYRECT-OCCSQVGLSA-N',\n",
      "            'isomericSMILES': 'OC[C@@H]1N(C)CC[C@H]1c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O',\n",
      "            'iupacName': '2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one',\n",
      "            'label': 'riviciclib',\n",
      "            'ligandName': 'riviciclib',\n",
      "            'synonym': 'P276-00',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7934'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80830'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 4',\n",
      "            'nomenclature': 'cyclin dependent kinase 4',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1976'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK4 subfamily',\n",
      "            'targetFamilyName': 'CDK4 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily488'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17363486'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.25,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80747'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CN1CCN(CC1)c1nc(C=Cc2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'comment': 'ENMD-2076 is an orally-active, Aurora A/angiogenic '\n",
      "                       'kinase inhibitor. It inhibits a distinct profile of '\n",
      "                       'angiogenic tyrosine kinases in addition to the Aurora '\n",
      "                       'A kinase. These angiogenic targets include VEGFR, Flt3 '\n",
      "                       'and FGFR3 kinases, which have been shown to play '\n",
      "                       'important roles in the pathology of several cancers.',\n",
      "            'inChI': 'InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+',\n",
      "            'inChIKey': 'BLQYVHBZHAISJM-CMDGGOBGSA-N',\n",
      "            'isomericSMILES': 'CN1CCN(CC1)c1nc(/C=C/c2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'iupacName': '6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine',\n",
      "            'label': 'ENMD-2076',\n",
      "            'ligandName': 'ENMD-2076',\n",
      "            'synonym': 'ENMD 2076',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7885'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80747'},\n",
      "           'hasTarget',\n",
      "           {'label': 'platelet derived growth factor receptor alpha',\n",
      "            'nomenclature': 'platelet derived growth factor receptor alpha',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1803'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family',\n",
      "            'targetFamilyName': 'Type III RTKs: PDGFR, CSFR, Kit, FLT3 '\n",
      "                                'receptor family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily322'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/19320489'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.300000190734863,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80781'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80781'},\n",
      "           'hasTarget',\n",
      "           {'label': 'glycogen synthase kinase 3 beta',\n",
      "            'nomenclature': 'glycogen synthase kinase 3 beta',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2030'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'GSK subfamily',\n",
      "            'targetFamilyName': 'GSK subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily509'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/15486189'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 9.0,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79363'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'OCCC1CCCCN1c1cc(NCc2ccc[n+](c2)[O-])n2c(n1)c(CC)cn2',\n",
      "            'comment': 'Dinaciclib is a potent cyclin-dependent kinase (CDK) '\n",
      "                       'inhibitor, inhibiting the CDK4 and 6 isoforms '\n",
      "                       '<Reference id=24187/>. Dinaciclib has also been '\n",
      "                       'reported to interact with the acetyl-lysine '\n",
      "                       'recognition domain of the bromodomain testis-specific '\n",
      "                       'protein BRDT <Reference id=24187/>. BRDT is a member '\n",
      "                       'of the BET family of bromodomain-containing proteins '\n",
      "                       'which are considered to be atypical '\n",
      "                       'kinases.<br><br><b>SARS-CoV-2: </b>SARS-CoV-2 may '\n",
      "                       'regulate the host cell cycle to enhance viral '\n",
      "                       'replication, and <i>in vitro</i> phosphoproteomics '\n",
      "                       'analysis suggests that viral hijacking of the CDK '\n",
      "                       'signalling pathway may, at least in part, mediate this '\n",
      "                       'mechanism <Reference id=39830/>. Pharmacological '\n",
      "                       'inhibition of the CDK pathway with dinaciclib has '\n",
      "                       'anti-SARS-CoV-2 activity in two model cells lines, '\n",
      "                       'A549-ACE2 cells (IC<sub>50</sub> 32 nM) and Vero E6 '\n",
      "                       'cells (IC<sub>50</sub> 127 nM).',\n",
      "            'inChI': 'InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1',\n",
      "            'inChIKey': 'PIMQWRZWLQKKBJ-SFHVURJKSA-N',\n",
      "            'isomericSMILES': 'OCC[C@@H]1CCCCN1c1cc(NCc2ccc[n+](c2)[O-])n2c(n1)c(CC)cn2',\n",
      "            'iupacName': '2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol',\n",
      "            'label': 'dinaciclib',\n",
      "            'ligandName': 'dinaciclib',\n",
      "            'synonym': 'SCH727965',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7379'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79363'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 2',\n",
      "            'nomenclature': 'cyclin dependent kinase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1973'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK1 subfamily',\n",
      "            'targetFamilyName': 'CDK1 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily492'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/24007471'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.699999809265137,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity86311'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'OCCC1CCCCN1c1cc(NCc2ccc[n+](c2)[O-])n2c(n1)c(CC)cn2',\n",
      "            'comment': 'Dinaciclib is a potent cyclin-dependent kinase (CDK) '\n",
      "                       'inhibitor, inhibiting the CDK4 and 6 isoforms '\n",
      "                       '<Reference id=24187/>. Dinaciclib has also been '\n",
      "                       'reported to interact with the acetyl-lysine '\n",
      "                       'recognition domain of the bromodomain testis-specific '\n",
      "                       'protein BRDT <Reference id=24187/>. BRDT is a member '\n",
      "                       'of the BET family of bromodomain-containing proteins '\n",
      "                       'which are considered to be atypical '\n",
      "                       'kinases.<br><br><b>SARS-CoV-2: </b>SARS-CoV-2 may '\n",
      "                       'regulate the host cell cycle to enhance viral '\n",
      "                       'replication, and <i>in vitro</i> phosphoproteomics '\n",
      "                       'analysis suggests that viral hijacking of the CDK '\n",
      "                       'signalling pathway may, at least in part, mediate this '\n",
      "                       'mechanism <Reference id=39830/>. Pharmacological '\n",
      "                       'inhibition of the CDK pathway with dinaciclib has '\n",
      "                       'anti-SARS-CoV-2 activity in two model cells lines, '\n",
      "                       'A549-ACE2 cells (IC<sub>50</sub> 32 nM) and Vero E6 '\n",
      "                       'cells (IC<sub>50</sub> 127 nM).',\n",
      "            'inChI': 'InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1',\n",
      "            'inChIKey': 'PIMQWRZWLQKKBJ-SFHVURJKSA-N',\n",
      "            'isomericSMILES': 'OCC[C@@H]1CCCCN1c1cc(NCc2ccc[n+](c2)[O-])n2c(n1)c(CC)cn2',\n",
      "            'iupacName': '2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol',\n",
      "            'label': 'dinaciclib',\n",
      "            'ligandName': 'dinaciclib',\n",
      "            'synonym': 'SCH727965',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7379'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction86311'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 2',\n",
      "            'nomenclature': 'cyclin dependent kinase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1973'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK1 subfamily',\n",
      "            'targetFamilyName': 'CDK1 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily492'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/30943029'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.220000267028809,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity82206'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CC(n1c(C)ncc1c1ccnc(n1)Nc1ccc(cc1)S(=O)(=O)C)C',\n",
      "            'comment': 'AZD5438 is a potent oral inhibitor of cyclin dependent '\n",
      "                       'kinases (CDKs) 1, 2 and 9 <Reference id=28188/>.',\n",
      "            'inChI': 'InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)',\n",
      "            'inChIKey': 'WJRRGYBTGDJBFX-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'CC(n1c(C)ncc1c1ccnc(n1)Nc1ccc(cc1)S(=O)(=O)C)C',\n",
      "            'iupacName': '4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine',\n",
      "            'label': 'AZD5438',\n",
      "            'ligandName': 'AZD5438',\n",
      "            'synonym': 'AZD-5438',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand8473'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction82206'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 2',\n",
      "            'nomenclature': 'cyclin dependent kinase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1973'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK1 subfamily',\n",
      "            'targetFamilyName': 'CDK1 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily492'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/19509270'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.440000057220459,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80746'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CN1CCN(CC1)c1nc(C=Cc2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'comment': 'ENMD-2076 is an orally-active, Aurora A/angiogenic '\n",
      "                       'kinase inhibitor. It inhibits a distinct profile of '\n",
      "                       'angiogenic tyrosine kinases in addition to the Aurora '\n",
      "                       'A kinase. These angiogenic targets include VEGFR, Flt3 '\n",
      "                       'and FGFR3 kinases, which have been shown to play '\n",
      "                       'important roles in the pathology of several cancers.',\n",
      "            'inChI': 'InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+',\n",
      "            'inChIKey': 'BLQYVHBZHAISJM-CMDGGOBGSA-N',\n",
      "            'isomericSMILES': 'CN1CCN(CC1)c1nc(/C=C/c2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'iupacName': '6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine',\n",
      "            'label': 'ENMD-2076',\n",
      "            'ligandName': 'ENMD-2076',\n",
      "            'synonym': 'ENMD 2076',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7885'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80746'},\n",
      "           'hasTarget',\n",
      "           {'label': 'kinase insert domain receptor',\n",
      "            'nomenclature': 'kinase insert domain receptor',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1813'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Type IV RTKs: VEGF (vascular endothelial growth factor) '\n",
      "                     'receptor family',\n",
      "            'targetFamilyName': 'Type IV RTKs: VEGF (vascular endothelial '\n",
      "                                'growth factor) receptor family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily324'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/19320489'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.520000457763672,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80745'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CN1CCN(CC1)c1nc(C=Cc2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'comment': 'ENMD-2076 is an orally-active, Aurora A/angiogenic '\n",
      "                       'kinase inhibitor. It inhibits a distinct profile of '\n",
      "                       'angiogenic tyrosine kinases in addition to the Aurora '\n",
      "                       'A kinase. These angiogenic targets include VEGFR, Flt3 '\n",
      "                       'and FGFR3 kinases, which have been shown to play '\n",
      "                       'important roles in the pathology of several cancers.',\n",
      "            'inChI': 'InChI=1S/C21H25N7/c1-16-14-20(26-25-16)23-19-15-21(28-12-10-27(2)11-13-28)24-18(22-19)9-8-17-6-4-3-5-7-17/h3-9,14-15H,10-13H2,1-2H3,(H2,22,23,24,25,26)/b9-8+',\n",
      "            'inChIKey': 'BLQYVHBZHAISJM-CMDGGOBGSA-N',\n",
      "            'isomericSMILES': 'CN1CCN(CC1)c1nc(/C=C/c2ccccc2)nc(c1)Nc1n[nH]c(c1)C',\n",
      "            'iupacName': '6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine',\n",
      "            'label': 'ENMD-2076',\n",
      "            'ligandName': 'ENMD-2076',\n",
      "            'synonym': 'ENMD 2076',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7885'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80745'},\n",
      "           'hasTarget',\n",
      "           {'label': 'fms related receptor tyrosine kinase 3',\n",
      "            'nomenclature': 'fms related receptor tyrosine kinase 3',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1807'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family',\n",
      "            'targetFamilyName': 'Type III RTKs: PDGFR, CSFR, Kit, FLT3 '\n",
      "                                'receptor family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily322'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/19320489'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.019999980926514,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80778'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80778'},\n",
      "           'hasTarget',\n",
      "           {'label': 'mitogen-activated protein kinase 14',\n",
      "            'nomenclature': 'mitogen-activated protein kinase 14',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1499'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'p38 subfamily',\n",
      "            'targetFamilyName': 'p38 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily519'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17292828'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 9.0,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79365'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'OCCC1CCCCN1c1cc(NCc2ccc[n+](c2)[O-])n2c(n1)c(CC)cn2',\n",
      "            'comment': 'Dinaciclib is a potent cyclin-dependent kinase (CDK) '\n",
      "                       'inhibitor, inhibiting the CDK4 and 6 isoforms '\n",
      "                       '<Reference id=24187/>. Dinaciclib has also been '\n",
      "                       'reported to interact with the acetyl-lysine '\n",
      "                       'recognition domain of the bromodomain testis-specific '\n",
      "                       'protein BRDT <Reference id=24187/>. BRDT is a member '\n",
      "                       'of the BET family of bromodomain-containing proteins '\n",
      "                       'which are considered to be atypical '\n",
      "                       'kinases.<br><br><b>SARS-CoV-2: </b>SARS-CoV-2 may '\n",
      "                       'regulate the host cell cycle to enhance viral '\n",
      "                       'replication, and <i>in vitro</i> phosphoproteomics '\n",
      "                       'analysis suggests that viral hijacking of the CDK '\n",
      "                       'signalling pathway may, at least in part, mediate this '\n",
      "                       'mechanism <Reference id=39830/>. Pharmacological '\n",
      "                       'inhibition of the CDK pathway with dinaciclib has '\n",
      "                       'anti-SARS-CoV-2 activity in two model cells lines, '\n",
      "                       'A549-ACE2 cells (IC<sub>50</sub> 32 nM) and Vero E6 '\n",
      "                       'cells (IC<sub>50</sub> 127 nM).',\n",
      "            'inChI': 'InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1',\n",
      "            'inChIKey': 'PIMQWRZWLQKKBJ-SFHVURJKSA-N',\n",
      "            'isomericSMILES': 'OCC[C@@H]1CCCCN1c1cc(NCc2ccc[n+](c2)[O-])n2c(n1)c(CC)cn2',\n",
      "            'iupacName': '2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol',\n",
      "            'label': 'dinaciclib',\n",
      "            'ligandName': 'dinaciclib',\n",
      "            'synonym': 'SCH727965',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7379'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79365'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 5',\n",
      "            'nomenclature': 'cyclin dependent kinase 5',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1977'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK5 subfamily',\n",
      "            'targetFamilyName': 'CDK5 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily495'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/24007471'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.399999618530273,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79366'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'OCCC1CCCCN1c1cc(NCc2ccc[n+](c2)[O-])n2c(n1)c(CC)cn2',\n",
      "            'comment': 'Dinaciclib is a potent cyclin-dependent kinase (CDK) '\n",
      "                       'inhibitor, inhibiting the CDK4 and 6 isoforms '\n",
      "                       '<Reference id=24187/>. Dinaciclib has also been '\n",
      "                       'reported to interact with the acetyl-lysine '\n",
      "                       'recognition domain of the bromodomain testis-specific '\n",
      "                       'protein BRDT <Reference id=24187/>. BRDT is a member '\n",
      "                       'of the BET family of bromodomain-containing proteins '\n",
      "                       'which are considered to be atypical '\n",
      "                       'kinases.<br><br><b>SARS-CoV-2: </b>SARS-CoV-2 may '\n",
      "                       'regulate the host cell cycle to enhance viral '\n",
      "                       'replication, and <i>in vitro</i> phosphoproteomics '\n",
      "                       'analysis suggests that viral hijacking of the CDK '\n",
      "                       'signalling pathway may, at least in part, mediate this '\n",
      "                       'mechanism <Reference id=39830/>. Pharmacological '\n",
      "                       'inhibition of the CDK pathway with dinaciclib has '\n",
      "                       'anti-SARS-CoV-2 activity in two model cells lines, '\n",
      "                       'A549-ACE2 cells (IC<sub>50</sub> 32 nM) and Vero E6 '\n",
      "                       'cells (IC<sub>50</sub> 127 nM).',\n",
      "            'inChI': 'InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1',\n",
      "            'inChIKey': 'PIMQWRZWLQKKBJ-SFHVURJKSA-N',\n",
      "            'isomericSMILES': 'OCC[C@@H]1CCCCN1c1cc(NCc2ccc[n+](c2)[O-])n2c(n1)c(CC)cn2',\n",
      "            'iupacName': '2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol',\n",
      "            'label': 'dinaciclib',\n",
      "            'ligandName': 'dinaciclib',\n",
      "            'synonym': 'SCH727965',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7379'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79366'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 9',\n",
      "            'nomenclature': 'cyclin dependent kinase 9',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1981'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK9 subfamily',\n",
      "            'targetFamilyName': 'CDK9 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily489'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/24007471'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.699999809265137,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80832'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'OCC1N(C)CCC1c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O',\n",
      "            'comment': 'Riviciclib is a flavone based cyclin dependent kinase '\n",
      "                       '(CDK) inhibitor with potential antineoplastic activity '\n",
      "                       '<Reference id=26250/>.',\n",
      "            'inChI': 'InChI=1S/C21H20ClNO5/c1-23-7-6-12(14(23)10-24)19-15(25)8-16(26)20-17(27)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,14,24-26H,6-7,10H2,1H3/t12-,14+/m1/s1',\n",
      "            'inChIKey': 'QLUYMIVVAYRECT-OCCSQVGLSA-N',\n",
      "            'isomericSMILES': 'OC[C@@H]1N(C)CC[C@H]1c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O',\n",
      "            'iupacName': '2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one',\n",
      "            'label': 'riviciclib',\n",
      "            'ligandName': 'riviciclib',\n",
      "            'synonym': 'P276-00',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7934'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80832'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 9',\n",
      "            'nomenclature': 'cyclin dependent kinase 9',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1981'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK9 subfamily',\n",
      "            'targetFamilyName': 'CDK9 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily489'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17363486'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.699999809265137,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity82208'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CC(n1c(C)ncc1c1ccnc(n1)Nc1ccc(cc1)S(=O)(=O)C)C',\n",
      "            'comment': 'AZD5438 is a potent oral inhibitor of cyclin dependent '\n",
      "                       'kinases (CDKs) 1, 2 and 9 <Reference id=28188/>.',\n",
      "            'inChI': 'InChI=1S/C18H21N5O2S/c1-12(2)23-13(3)20-11-17(23)16-9-10-19-18(22-16)21-14-5-7-15(8-6-14)26(4,24)25/h5-12H,1-4H3,(H,19,21,22)',\n",
      "            'inChIKey': 'WJRRGYBTGDJBFX-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'CC(n1c(C)ncc1c1ccnc(n1)Nc1ccc(cc1)S(=O)(=O)C)C',\n",
      "            'iupacName': '4-(2-methyl-3-propan-2-ylimidazol-4-yl)-N-(4-methylsulfonylphenyl)pyrimidin-2-amine',\n",
      "            'label': 'AZD5438',\n",
      "            'ligandName': 'AZD5438',\n",
      "            'synonym': 'AZD-5438',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand8473'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction82208'},\n",
      "           'hasTarget',\n",
      "           {'label': 'cyclin dependent kinase 9',\n",
      "            'nomenclature': 'cyclin dependent kinase 9',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1981'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'CDK9 subfamily',\n",
      "            'targetFamilyName': 'CDK9 subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily489'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/19509270'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.539999961853027,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80789'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80789'},\n",
      "           'hasTarget',\n",
      "           {'label': 'protein kinase C alpha',\n",
      "            'nomenclature': 'protein kinase C alpha',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1482'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Delta subfamily',\n",
      "            'targetFamilyName': 'Delta subfamily',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily533'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/8022414'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#NoAction'},\n",
      "  'af': {'hasMedianValue': 8.0,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity88388'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88388'},\n",
      "           'hasTarget',\n",
      "           {'label': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'nomenclature': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target3072'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Chromatin modifying enzymes (<i>Plasmodium</i> spp.)',\n",
      "            'targetFamilyName': 'Chromatin modifying enzymes '\n",
      "                                '(<i>Plasmodium</i> spp.)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily1059'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/26199860'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#NoAction'},\n",
      "  'af': {'hasMedianValue': 8.050000190734863,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity88389'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88389'},\n",
      "           'hasTarget',\n",
      "           {'label': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'nomenclature': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target3072'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Chromatin modifying enzymes (<i>Plasmodium</i> spp.)',\n",
      "            'targetFamilyName': 'Chromatin modifying enzymes '\n",
      "                                '(<i>Plasmodium</i> spp.)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily1059'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/28107750'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#NoAction'},\n",
      "  'af': {'hasMedianValue': 7.519999980926514,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity88418'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88418'},\n",
      "           'hasTarget',\n",
      "           {'label': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'nomenclature': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target3072'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Chromatin modifying enzymes (<i>Plasmodium</i> spp.)',\n",
      "            'targetFamilyName': 'Chromatin modifying enzymes '\n",
      "                                '(<i>Plasmodium</i> spp.)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily1059'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/26199860'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#NoAction'},\n",
      "  'af': {'hasMedianValue': 6.03000020980835,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity88419'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88419'},\n",
      "           'hasTarget',\n",
      "           {'label': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'nomenclature': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target3072'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Chromatin modifying enzymes (<i>Plasmodium</i> spp.)',\n",
      "            'targetFamilyName': 'Chromatin modifying enzymes '\n",
      "                                '(<i>Plasmodium</i> spp.)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily1059'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/24434750'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#NoAction'},\n",
      "  'af': {'hasMedianValue': 6.929999828338623,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity88420'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88420'},\n",
      "           'hasTarget',\n",
      "           {'label': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'nomenclature': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target3072'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Chromatin modifying enzymes (<i>Plasmodium</i> spp.)',\n",
      "            'targetFamilyName': 'Chromatin modifying enzymes '\n",
      "                                '(<i>Plasmodium</i> spp.)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily1059'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/24434750'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#NoAction'},\n",
      "  'af': {'hasMedianValue': 6.829999923706055,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity88421'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction88421'},\n",
      "           'hasTarget',\n",
      "           {'label': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'nomenclature': 'Plasmodium falciparum histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target3072'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Chromatin modifying enzymes (<i>Plasmodium</i> spp.)',\n",
      "            'targetFamilyName': 'Chromatin modifying enzymes '\n",
      "                                '(<i>Plasmodium</i> spp.)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily1059'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/24434750'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.510000228881836,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79208'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'Clc1c[nH]c2c1cccc2NS(=O)(=O)c1ccc(cc1)S(=O)(=O)N',\n",
      "            'comment': 'Indisulam is an anticancer sulfonamide that is in '\n",
      "                       'clinical development. This compound belongs to the '\n",
      "                       'family of carbonic anhydrase inhibitors. It also '\n",
      "                       'behaves as a type of molecular glue that targets '\n",
      "                       'certain proteins for ubiquitination and proteasomal '\n",
      "                       'degradation <Reference id=42961/><Reference '\n",
      "                       'id=42962/>, by bringing them into the proximity the '\n",
      "                       'CUL4-DDB1-DDA1-DCAF15 E3 ubiquitin ligase complex.',\n",
      "            'inChI': 'InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)',\n",
      "            'inChIKey': 'SETFNECMODOHTO-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'Clc1c[nH]c2c1cccc2NS(=O)(=O)c1ccc(cc1)S(=O)(=O)N',\n",
      "            'iupacName': 'N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide',\n",
      "            'label': 'indisulam',\n",
      "            'ligandName': 'indisulam',\n",
      "            'synonym': 'E7070',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7046'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79208'},\n",
      "           'hasTarget',\n",
      "           {'label': 'carbonic anhydrase 1',\n",
      "            'nomenclature': 'carbonic anhydrase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2597'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Carbonic anhydrases',\n",
      "            'targetFamilyName': 'Carbonic anhydrases',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily842'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/23965175'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.610000133514404,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79806'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79806'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 8',\n",
      "            'nomenclature': 'histone deacetylase 8',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2619'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.059999942779541,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79873'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccn(c1)S(=O)(=O)c1ccc(cc1)CN(C)C',\n",
      "            'comment': 'Resminostat is an HDAC inhibitor with selectivity for '\n",
      "                       'HDACs 1, 3 and 6, with significantly lower affinity '\n",
      "                       'for HDAC8 <Reference id=24592/>.',\n",
      "            'inChI': 'InChI=1S/C16H19N3O4S/c1-18(2)11-13-3-6-15(7-4-13)24(22,23)19-10-9-14(12-19)5-8-16(20)17-21/h3-10,12,21H,11H2,1-2H3,(H,17,20)/b8-5+',\n",
      "            'inChIKey': 'FECGNJPYVFEKOD-VMPITWQZSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccn(c1)S(=O)(=O)c1ccc(cc1)CN(C)C',\n",
      "            'iupacName': '(E)-3-[1-[4-(dimethylaminomethyl)phenyl]sulfonylpyrrol-3-yl]-N-hydroxyprop-2-enamide',\n",
      "            'label': 'resminostat',\n",
      "            'ligandName': 'resminostat',\n",
      "            'synonym': 'BYK408740',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7502'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79873'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 8',\n",
      "            'nomenclature': 'histone deacetylase 8',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2619'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20201941'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.0,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79309'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1',\n",
      "            'comment': 'Rocilinostat is an investigational HDAC6 inhibitor '\n",
      "                       '<Reference id=24127/>. But note that it exhibits only '\n",
      "                       '~10-fold enzymic selectivity against the class I '\n",
      "                       'isoform, HDAC1.',\n",
      "            'inChI': 'InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)',\n",
      "            'inChIKey': 'QGZYDVAGYRLSKP-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1',\n",
      "            'iupacName': 'N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide',\n",
      "            'label': 'ricolinostat',\n",
      "            'ligandName': 'ricolinostat',\n",
      "            'synonym': 'ACY-1215',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7010'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79309'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 8',\n",
      "            'nomenclature': 'histone deacetylase 8',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2619'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/22262760'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.670000076293945,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79840'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79840'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 8',\n",
      "            'nomenclature': 'histone deacetylase 8',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2619'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.599999904632568,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79849'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79849'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 8',\n",
      "            'nomenclature': 'histone deacetylase 8',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2619'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.440000057220459,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79151'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'comment': 'Entinostat (MS-275) inhibits Class I histone '\n",
      "                       'deacetylases (HDACs 1, 2, 3 & 8), but has been shown '\n",
      "                       'to be somewhat selective for HDAC1 <Reference '\n",
      "                       'id=23898/><Reference id=23750/>. Studies in rodent '\n",
      "                       'models of inflammation suggest that inhibition by '\n",
      "                       'entinostat may be clinically useful <Reference '\n",
      "                       'id=23899/><Reference id=23900/><Reference '\n",
      "                       'id=23901/><Reference id=23902/>, perhaps more so than '\n",
      "                       'broader acting Class I HDAC inhibitors such as '\n",
      "                       'vorinostat (SAHA) <Reference id=23902/>.',\n",
      "            'inChI': 'InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)',\n",
      "            'inChIKey': 'INVTYAOGFAGBOE-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'iupacName': 'pyridin-3-ylmethyl '\n",
      "                         'N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate',\n",
      "            'label': 'entinostat',\n",
      "            'ligandName': 'entinostat',\n",
      "            'synonym': 'SNDX-275',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7007'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79151'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 3',\n",
      "            'nomenclature': 'histone deacetylase 3',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2617'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.289999961853027,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79308'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1',\n",
      "            'comment': 'Rocilinostat is an investigational HDAC6 inhibitor '\n",
      "                       '<Reference id=24127/>. But note that it exhibits only '\n",
      "                       '~10-fold enzymic selectivity against the class I '\n",
      "                       'isoform, HDAC1.',\n",
      "            'inChI': 'InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)',\n",
      "            'inChIKey': 'QGZYDVAGYRLSKP-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1',\n",
      "            'iupacName': 'N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide',\n",
      "            'label': 'ricolinostat',\n",
      "            'ligandName': 'ricolinostat',\n",
      "            'synonym': 'ACY-1215',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7010'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79308'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 3',\n",
      "            'nomenclature': 'histone deacetylase 3',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2617'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/22262760'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.399999618530273,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79802'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79802'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 3',\n",
      "            'nomenclature': 'histone deacetylase 3',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2617'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 5.639999866485596,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79855'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'comment': 'Entinostat (MS-275) inhibits Class I histone '\n",
      "                       'deacetylases (HDACs 1, 2, 3 & 8), but has been shown '\n",
      "                       'to be somewhat selective for HDAC1 <Reference '\n",
      "                       'id=23898/><Reference id=23750/>. Studies in rodent '\n",
      "                       'models of inflammation suggest that inhibition by '\n",
      "                       'entinostat may be clinically useful <Reference '\n",
      "                       'id=23899/><Reference id=23900/><Reference '\n",
      "                       'id=23901/><Reference id=23902/>, perhaps more so than '\n",
      "                       'broader acting Class I HDAC inhibitors such as '\n",
      "                       'vorinostat (SAHA) <Reference id=23902/>.',\n",
      "            'inChI': 'InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)',\n",
      "            'inChIKey': 'INVTYAOGFAGBOE-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'iupacName': 'pyridin-3-ylmethyl '\n",
      "                         'N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate',\n",
      "            'label': 'entinostat',\n",
      "            'ligandName': 'entinostat',\n",
      "            'synonym': 'SNDX-275',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7007'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79855'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 3',\n",
      "            'nomenclature': 'histone deacetylase 3',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2617'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.819999694824219,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79844'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79844'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 3',\n",
      "            'nomenclature': 'histone deacetylase 3',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2617'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.300000190734863,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79871'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccn(c1)S(=O)(=O)c1ccc(cc1)CN(C)C',\n",
      "            'comment': 'Resminostat is an HDAC inhibitor with selectivity for '\n",
      "                       'HDACs 1, 3 and 6, with significantly lower affinity '\n",
      "                       'for HDAC8 <Reference id=24592/>.',\n",
      "            'inChI': 'InChI=1S/C16H19N3O4S/c1-18(2)11-13-3-6-15(7-4-13)24(22,23)19-10-9-14(12-19)5-8-16(20)17-21/h3-10,12,21H,11H2,1-2H3,(H,17,20)/b8-5+',\n",
      "            'inChIKey': 'FECGNJPYVFEKOD-VMPITWQZSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccn(c1)S(=O)(=O)c1ccc(cc1)CN(C)C',\n",
      "            'iupacName': '(E)-3-[1-[4-(dimethylaminomethyl)phenyl]sulfonylpyrrol-3-yl]-N-hydroxyprop-2-enamide',\n",
      "            'label': 'resminostat',\n",
      "            'ligandName': 'resminostat',\n",
      "            'synonym': 'BYK408740',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7502'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79871'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 3',\n",
      "            'nomenclature': 'histone deacetylase 3',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2617'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20201941'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.099999904632568,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79868'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'O=C(Nc1ccc(cc1N)F)C=Cc1cnn(c1)CC=Cc1ccccc1',\n",
      "            'comment': 'RGFP966 is a selective inhibitor of histone '\n",
      "                       'deacetylase 3 (HDAC3) <Reference id=24589/>. In rodent '\n",
      "                       'studies, RGFP966-induced inhibition of HDAC3 appears '\n",
      "                       'to enhance memory processes involved in extinction of '\n",
      "                       'drug-seeking behaviour <Reference id=24589/>.',\n",
      "            'inChI': 'InChI=1S/C21H19FN4O/c22-18-9-10-20(19(23)13-18)25-21(27)11-8-17-14-24-26(15-17)12-4-7-16-5-2-1-3-6-16/h1-11,13-15H,12,23H2,(H,25,27)/b7-4+,11-8+',\n",
      "            'inChIKey': 'BLVQHYHDYFTPDV-VCABWLAWSA-N',\n",
      "            'isomericSMILES': 'O=C(Nc1ccc(cc1N)F)/C=C/c1cnn(c1)C/C=C/c1ccccc1',\n",
      "            'iupacName': '(2E)-N-(2-amino-4-fluorophenyl)-3-{1-[(2E)-3-phenylprop-2-en-1-yl]-1H-pyrazol-4-yl}prop-2-enamide',\n",
      "            'label': 'RGFP966',\n",
      "            'ligandName': 'RGFP966',\n",
      "            'synonym': 'RGFP-966',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7500'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79868'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 3',\n",
      "            'nomenclature': 'histone deacetylase 3',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2617'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/23297220'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.519999980926514,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80048'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80048'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 3',\n",
      "            'nomenclature': 'histone deacetylase 3',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2617'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.190000057220459,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79148'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'comment': 'Entinostat (MS-275) inhibits Class I histone '\n",
      "                       'deacetylases (HDACs 1, 2, 3 & 8), but has been shown '\n",
      "                       'to be somewhat selective for HDAC1 <Reference '\n",
      "                       'id=23898/><Reference id=23750/>. Studies in rodent '\n",
      "                       'models of inflammation suggest that inhibition by '\n",
      "                       'entinostat may be clinically useful <Reference '\n",
      "                       'id=23899/><Reference id=23900/><Reference '\n",
      "                       'id=23901/><Reference id=23902/>, perhaps more so than '\n",
      "                       'broader acting Class I HDAC inhibitors such as '\n",
      "                       'vorinostat (SAHA) <Reference id=23902/>.',\n",
      "            'inChI': 'InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)',\n",
      "            'inChIKey': 'INVTYAOGFAGBOE-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'iupacName': 'pyridin-3-ylmethyl '\n",
      "                         'N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate',\n",
      "            'label': 'entinostat',\n",
      "            'ligandName': 'entinostat',\n",
      "            'synonym': 'SNDX-275',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7007'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79148'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 2',\n",
      "            'nomenclature': 'histone deacetylase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2616'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.320000171661377,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79307'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1',\n",
      "            'comment': 'Rocilinostat is an investigational HDAC6 inhibitor '\n",
      "                       '<Reference id=24127/>. But note that it exhibits only '\n",
      "                       '~10-fold enzymic selectivity against the class I '\n",
      "                       'isoform, HDAC1.',\n",
      "            'inChI': 'InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)',\n",
      "            'inChIKey': 'QGZYDVAGYRLSKP-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1',\n",
      "            'iupacName': 'N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide',\n",
      "            'label': 'ricolinostat',\n",
      "            'ligandName': 'ricolinostat',\n",
      "            'synonym': 'ACY-1215',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7010'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79307'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 2',\n",
      "            'nomenclature': 'histone deacetylase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2616'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/22262760'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.520000457763672,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79801'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79801'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 2',\n",
      "            'nomenclature': 'histone deacetylase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2616'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 5.940000057220459,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79854'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'comment': 'Entinostat (MS-275) inhibits Class I histone '\n",
      "                       'deacetylases (HDACs 1, 2, 3 & 8), but has been shown '\n",
      "                       'to be somewhat selective for HDAC1 <Reference '\n",
      "                       'id=23898/><Reference id=23750/>. Studies in rodent '\n",
      "                       'models of inflammation suggest that inhibition by '\n",
      "                       'entinostat may be clinically useful <Reference '\n",
      "                       'id=23899/><Reference id=23900/><Reference '\n",
      "                       'id=23901/><Reference id=23902/>, perhaps more so than '\n",
      "                       'broader acting Class I HDAC inhibitors such as '\n",
      "                       'vorinostat (SAHA) <Reference id=23902/>.',\n",
      "            'inChI': 'InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)',\n",
      "            'inChIKey': 'INVTYAOGFAGBOE-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'iupacName': 'pyridin-3-ylmethyl '\n",
      "                         'N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate',\n",
      "            'label': 'entinostat',\n",
      "            'ligandName': 'entinostat',\n",
      "            'synonym': 'SNDX-275',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7007'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79854'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 2',\n",
      "            'nomenclature': 'histone deacetylase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2616'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.900000095367432,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79835'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79835'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 2',\n",
      "            'nomenclature': 'histone deacetylase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2616'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 9.069999694824219,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79843'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79843'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 2',\n",
      "            'nomenclature': 'histone deacetylase 2',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2616'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.520000457763672,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79807'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79807'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 9',\n",
      "            'nomenclature': 'histone deacetylase 9',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2620'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.889999866485596,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79841'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79841'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 9',\n",
      "            'nomenclature': 'histone deacetylase 9',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2620'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.599999904632568,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79850'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79850'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 9',\n",
      "            'nomenclature': 'histone deacetylase 9',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2620'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.300000190734863,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79856'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'comment': 'Entinostat (MS-275) inhibits Class I histone '\n",
      "                       'deacetylases (HDACs 1, 2, 3 & 8), but has been shown '\n",
      "                       'to be somewhat selective for HDAC1 <Reference '\n",
      "                       'id=23898/><Reference id=23750/>. Studies in rodent '\n",
      "                       'models of inflammation suggest that inhibition by '\n",
      "                       'entinostat may be clinically useful <Reference '\n",
      "                       'id=23899/><Reference id=23900/><Reference '\n",
      "                       'id=23901/><Reference id=23902/>, perhaps more so than '\n",
      "                       'broader acting Class I HDAC inhibitors such as '\n",
      "                       'vorinostat (SAHA) <Reference id=23902/>.',\n",
      "            'inChI': 'InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)',\n",
      "            'inChIKey': 'INVTYAOGFAGBOE-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'iupacName': 'pyridin-3-ylmethyl '\n",
      "                         'N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate',\n",
      "            'label': 'entinostat',\n",
      "            'ligandName': 'entinostat',\n",
      "            'synonym': 'SNDX-275',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7007'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79856'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 9',\n",
      "            'nomenclature': 'histone deacetylase 9',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2620'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.210000038146973,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79804'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79804'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 6',\n",
      "            'nomenclature': 'histone deacetylase 6',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2618'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 9.300000190734863,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity87533'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CCCCN(C(=O)Nc1ccccc1)Cc1ccc(cc1)C(=O)NO',\n",
      "            'comment': 'Nexturastat A is a potent and selective HDAC6 '\n",
      "                       'inhibitor <Reference id=24597/>.',\n",
      "            'inChI': 'InChI=1S/C19H23N3O3/c1-2-3-13-22(19(24)20-17-7-5-4-6-8-17)14-15-9-11-16(12-10-15)18(23)21-25/h4-12,25H,2-3,13-14H2,1H3,(H,20,24)(H,21,23)',\n",
      "            'inChIKey': 'JZWXMCPARMXZQV-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'CCCCN(C(=O)Nc1ccccc1)Cc1ccc(cc1)C(=O)NO',\n",
      "            'iupacName': '4-{[butyl(phenylcarbamoyl)amino]methyl}-N-hydroxybenzamide',\n",
      "            'label': 'nexturastat A',\n",
      "            'ligandName': 'nexturastat A',\n",
      "            'synonym': 'S7473',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7504'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction87533'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 6',\n",
      "            'nomenclature': 'histone deacetylase 6',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2618'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/32815366'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.329999923706055,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79310'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1',\n",
      "            'comment': 'Rocilinostat is an investigational HDAC6 inhibitor '\n",
      "                       '<Reference id=24127/>. But note that it exhibits only '\n",
      "                       '~10-fold enzymic selectivity against the class I '\n",
      "                       'isoform, HDAC1.',\n",
      "            'inChI': 'InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)',\n",
      "            'inChIKey': 'QGZYDVAGYRLSKP-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1',\n",
      "            'iupacName': 'N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide',\n",
      "            'label': 'ricolinostat',\n",
      "            'ligandName': 'ricolinostat',\n",
      "            'synonym': 'ACY-1215',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7010'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79310'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 6',\n",
      "            'nomenclature': 'histone deacetylase 6',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2618'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/22262760'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.090000152587891,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79838'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79838'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 6',\n",
      "            'nomenclature': 'histone deacetylase 6',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2618'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.800000190734863,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79847'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79847'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 6',\n",
      "            'nomenclature': 'histone deacetylase 6',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2618'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.139999866485596,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79872'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccn(c1)S(=O)(=O)c1ccc(cc1)CN(C)C',\n",
      "            'comment': 'Resminostat is an HDAC inhibitor with selectivity for '\n",
      "                       'HDACs 1, 3 and 6, with significantly lower affinity '\n",
      "                       'for HDAC8 <Reference id=24592/>.',\n",
      "            'inChI': 'InChI=1S/C16H19N3O4S/c1-18(2)11-13-3-6-15(7-4-13)24(22,23)19-10-9-14(12-19)5-8-16(20)17-21/h3-10,12,21H,11H2,1-2H3,(H,17,20)/b8-5+',\n",
      "            'inChIKey': 'FECGNJPYVFEKOD-VMPITWQZSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccn(c1)S(=O)(=O)c1ccc(cc1)CN(C)C',\n",
      "            'iupacName': '(E)-3-[1-[4-(dimethylaminomethyl)phenyl]sulfonylpyrrol-3-yl]-N-hydroxyprop-2-enamide',\n",
      "            'label': 'resminostat',\n",
      "            'ligandName': 'resminostat',\n",
      "            'synonym': 'BYK408740',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7502'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79872'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 6',\n",
      "            'nomenclature': 'histone deacetylase 6',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2618'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20201941'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.300000190734863,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79886'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CCCCN(C(=O)Nc1ccccc1)Cc1ccc(cc1)C(=O)NO',\n",
      "            'comment': 'Nexturastat A is a potent and selective HDAC6 '\n",
      "                       'inhibitor <Reference id=24597/>.',\n",
      "            'inChI': 'InChI=1S/C19H23N3O3/c1-2-3-13-22(19(24)20-17-7-5-4-6-8-17)14-15-9-11-16(12-10-15)18(23)21-25/h4-12,25H,2-3,13-14H2,1H3,(H,20,24)(H,21,23)',\n",
      "            'inChIKey': 'JZWXMCPARMXZQV-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'CCCCN(C(=O)Nc1ccccc1)Cc1ccc(cc1)C(=O)NO',\n",
      "            'iupacName': '4-{[butyl(phenylcarbamoyl)amino]methyl}-N-hydroxybenzamide',\n",
      "            'label': 'nexturastat A',\n",
      "            'ligandName': 'nexturastat A',\n",
      "            'synonym': 'S7473',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7504'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79886'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 6',\n",
      "            'nomenclature': 'histone deacetylase 6',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2618'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/23009203'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.659999847412109,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79144'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'comment': 'Entinostat (MS-275) inhibits Class I histone '\n",
      "                       'deacetylases (HDACs 1, 2, 3 & 8), but has been shown '\n",
      "                       'to be somewhat selective for HDAC1 <Reference '\n",
      "                       'id=23898/><Reference id=23750/>. Studies in rodent '\n",
      "                       'models of inflammation suggest that inhibition by '\n",
      "                       'entinostat may be clinically useful <Reference '\n",
      "                       'id=23899/><Reference id=23900/><Reference '\n",
      "                       'id=23901/><Reference id=23902/>, perhaps more so than '\n",
      "                       'broader acting Class I HDAC inhibitors such as '\n",
      "                       'vorinostat (SAHA) <Reference id=23902/>.',\n",
      "            'inChI': 'InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)',\n",
      "            'inChIKey': 'INVTYAOGFAGBOE-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'iupacName': 'pyridin-3-ylmethyl '\n",
      "                         'N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate',\n",
      "            'label': 'entinostat',\n",
      "            'ligandName': 'entinostat',\n",
      "            'synonym': 'SNDX-275',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7007'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79144'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 1',\n",
      "            'nomenclature': 'histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2658'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.239999771118164,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79306'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1',\n",
      "            'comment': 'Rocilinostat is an investigational HDAC6 inhibitor '\n",
      "                       '<Reference id=24127/>. But note that it exhibits only '\n",
      "                       '~10-fold enzymic selectivity against the class I '\n",
      "                       'isoform, HDAC1.',\n",
      "            'inChI': 'InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)',\n",
      "            'inChIKey': 'QGZYDVAGYRLSKP-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1',\n",
      "            'iupacName': 'N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide',\n",
      "            'label': 'ricolinostat',\n",
      "            'ligandName': 'ricolinostat',\n",
      "            'synonym': 'ACY-1215',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7010'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79306'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 1',\n",
      "            'nomenclature': 'histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2658'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/22262760'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.520000457763672,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79800'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79800'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 1',\n",
      "            'nomenclature': 'histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2658'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.739999771118164,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79853'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'comment': 'Entinostat (MS-275) inhibits Class I histone '\n",
      "                       'deacetylases (HDACs 1, 2, 3 & 8), but has been shown '\n",
      "                       'to be somewhat selective for HDAC1 <Reference '\n",
      "                       'id=23898/><Reference id=23750/>. Studies in rodent '\n",
      "                       'models of inflammation suggest that inhibition by '\n",
      "                       'entinostat may be clinically useful <Reference '\n",
      "                       'id=23899/><Reference id=23900/><Reference '\n",
      "                       'id=23901/><Reference id=23902/>, perhaps more so than '\n",
      "                       'broader acting Class I HDAC inhibitors such as '\n",
      "                       'vorinostat (SAHA) <Reference id=23902/>.',\n",
      "            'inChI': 'InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)',\n",
      "            'inChIKey': 'INVTYAOGFAGBOE-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N',\n",
      "            'iupacName': 'pyridin-3-ylmethyl '\n",
      "                         'N-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate',\n",
      "            'label': 'entinostat',\n",
      "            'ligandName': 'entinostat',\n",
      "            'synonym': 'SNDX-275',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7007'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79853'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 1',\n",
      "            'nomenclature': 'histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2658'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 5.519999980926514,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79885'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CCCCN(C(=O)Nc1ccccc1)Cc1ccc(cc1)C(=O)NO',\n",
      "            'comment': 'Nexturastat A is a potent and selective HDAC6 '\n",
      "                       'inhibitor <Reference id=24597/>.',\n",
      "            'inChI': 'InChI=1S/C19H23N3O3/c1-2-3-13-22(19(24)20-17-7-5-4-6-8-17)14-15-9-11-16(12-10-15)18(23)21-25/h4-12,25H,2-3,13-14H2,1H3,(H,20,24)(H,21,23)',\n",
      "            'inChIKey': 'JZWXMCPARMXZQV-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'CCCCN(C(=O)Nc1ccccc1)Cc1ccc(cc1)C(=O)NO',\n",
      "            'iupacName': '4-{[butyl(phenylcarbamoyl)amino]methyl}-N-hydroxybenzamide',\n",
      "            'label': 'nexturastat A',\n",
      "            'ligandName': 'nexturastat A',\n",
      "            'synonym': 'S7473',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7504'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79885'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 1',\n",
      "            'nomenclature': 'histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2658'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/23009203'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.389999866485596,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79834'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79834'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 1',\n",
      "            'nomenclature': 'histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2658'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 9.069999694824219,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79842'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79842'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 1',\n",
      "            'nomenclature': 'histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2658'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.369999885559082,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79870'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccn(c1)S(=O)(=O)c1ccc(cc1)CN(C)C',\n",
      "            'comment': 'Resminostat is an HDAC inhibitor with selectivity for '\n",
      "                       'HDACs 1, 3 and 6, with significantly lower affinity '\n",
      "                       'for HDAC8 <Reference id=24592/>.',\n",
      "            'inChI': 'InChI=1S/C16H19N3O4S/c1-18(2)11-13-3-6-15(7-4-13)24(22,23)19-10-9-14(12-19)5-8-16(20)17-21/h3-10,12,21H,11H2,1-2H3,(H,17,20)/b8-5+',\n",
      "            'inChIKey': 'FECGNJPYVFEKOD-VMPITWQZSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccn(c1)S(=O)(=O)c1ccc(cc1)CN(C)C',\n",
      "            'iupacName': '(E)-3-[1-[4-(dimethylaminomethyl)phenyl]sulfonylpyrrol-3-yl]-N-hydroxyprop-2-enamide',\n",
      "            'label': 'resminostat',\n",
      "            'ligandName': 'resminostat',\n",
      "            'synonym': 'BYK408740',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7502'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79870'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 1',\n",
      "            'nomenclature': 'histone deacetylase 1',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2658'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20201941'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.920000076293945,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79803'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79803'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 4',\n",
      "            'nomenclature': 'histone deacetylase 4',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2659'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.940000057220459,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79837'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79837'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 4',\n",
      "            'nomenclature': 'histone deacetylase 4',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2659'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.420000076293945,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79845'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79845'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 4',\n",
      "            'nomenclature': 'histone deacetylase 4',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2659'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.849999904632568,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79805'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'comment': 'Panobinostat is a non-selective histone deacetylase '\n",
      "                       '(HDAC) inhibitor <Reference id=24577/><Reference '\n",
      "                       'id=24578/>. The compound also has antimalarial '\n",
      "                       'activity. <br><br>The <b>Malaria</b> tab on this '\n",
      "                       'ligand page provides additional curator comments of '\n",
      "                       'relevance to the Guide to MALARIA PHARMACOLOGY.',\n",
      "            'inChI': 'InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+',\n",
      "            'inChIKey': 'FPOHNWQLNRZRFC-ZHACJKMWSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide',\n",
      "            'label': 'panobinostat',\n",
      "            'ligandName': 'panobinostat',\n",
      "            'synonym': 'LBH589',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7489'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79805'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 7',\n",
      "            'nomenclature': 'histone deacetylase 7',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2661'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.170000076293945,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79839'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79839'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 7',\n",
      "            'nomenclature': 'histone deacetylase 7',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2661'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/17868033'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 7.119999885559082,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79848'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79848'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 7',\n",
      "            'nomenclature': 'histone deacetylase 7',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2661'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.760000228881836,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79846'},\n",
      "  'path': [{'approved': 't',\n",
      "            'canonicalSMILES': 'ONC(=O)C=Cc1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'comment': 'Belinostat is a pan-histone deacetylase (HDAC) '\n",
      "                       'inhibitor <Reference id=24578/><Reference id=23750/>.',\n",
      "            'inChI': 'InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+',\n",
      "            'inChIKey': 'NCNRHFGMJRPRSK-MDZDMXLPSA-N',\n",
      "            'isomericSMILES': 'ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1',\n",
      "            'iupacName': '(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide',\n",
      "            'label': 'belinostat',\n",
      "            'ligandName': 'belinostat',\n",
      "            'synonym': 'Beleodaq&reg;',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7496'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79846'},\n",
      "           'hasTarget',\n",
      "           {'label': 'histone deacetylase 5',\n",
      "            'nomenclature': 'histone deacetylase 5',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2660'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'targetFamilyName': '3.5.1.- Histone deacetylases (HDACs)',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily848'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/20139990'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 8.470000267028809,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79212'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'Clc1c[nH]c2c1cccc2NS(=O)(=O)c1ccc(cc1)S(=O)(=O)N',\n",
      "            'comment': 'Indisulam is an anticancer sulfonamide that is in '\n",
      "                       'clinical development. This compound belongs to the '\n",
      "                       'family of carbonic anhydrase inhibitors. It also '\n",
      "                       'behaves as a type of molecular glue that targets '\n",
      "                       'certain proteins for ubiquitination and proteasomal '\n",
      "                       'degradation <Reference id=42961/><Reference '\n",
      "                       'id=42962/>, by bringing them into the proximity the '\n",
      "                       'CUL4-DDB1-DDA1-DCAF15 E3 ubiquitin ligase complex.',\n",
      "            'inChI': 'InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)',\n",
      "            'inChIKey': 'SETFNECMODOHTO-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'Clc1c[nH]c2c1cccc2NS(=O)(=O)c1ccc(cc1)S(=O)(=O)N',\n",
      "            'iupacName': 'N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide',\n",
      "            'label': 'indisulam',\n",
      "            'ligandName': 'indisulam',\n",
      "            'synonym': 'E7070',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7046'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79212'},\n",
      "           'hasTarget',\n",
      "           {'label': 'carbonic anhydrase 12',\n",
      "            'nomenclature': 'carbonic anhydrase 12',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2747'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Carbonic anhydrases',\n",
      "            'targetFamilyName': 'Carbonic anhydrases',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily842'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/23965175'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.909999847412109,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity79210'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'Clc1c[nH]c2c1cccc2NS(=O)(=O)c1ccc(cc1)S(=O)(=O)N',\n",
      "            'comment': 'Indisulam is an anticancer sulfonamide that is in '\n",
      "                       'clinical development. This compound belongs to the '\n",
      "                       'family of carbonic anhydrase inhibitors. It also '\n",
      "                       'behaves as a type of molecular glue that targets '\n",
      "                       'certain proteins for ubiquitination and proteasomal '\n",
      "                       'degradation <Reference id=42961/><Reference '\n",
      "                       'id=42962/>, by bringing them into the proximity the '\n",
      "                       'CUL4-DDB1-DDA1-DCAF15 E3 ubiquitin ligase complex.',\n",
      "            'inChI': 'InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20)',\n",
      "            'inChIKey': 'SETFNECMODOHTO-UHFFFAOYSA-N',\n",
      "            'isomericSMILES': 'Clc1c[nH]c2c1cccc2NS(=O)(=O)c1ccc(cc1)S(=O)(=O)N',\n",
      "            'iupacName': 'N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide',\n",
      "            'label': 'indisulam',\n",
      "            'ligandName': 'indisulam',\n",
      "            'synonym': 'E7070',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7046'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction79210'},\n",
      "           'hasTarget',\n",
      "           {'label': 'carbonic anhydrase 7',\n",
      "            'nomenclature': 'carbonic anhydrase 7',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target2749'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Carbonic anhydrases',\n",
      "            'targetFamilyName': 'Carbonic anhydrases',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily842'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/23965175'}},\n",
      " {'a': {'uri': 'https://rdf.guidetopharmacology.org/ns/gtpo#InhibitionAction'},\n",
      "  'af': {'hasMedianValue': 6.0,\n",
      "         'uri': 'https://rdf.guidetopharmacology.org/GRAC/affinity80783'},\n",
      "  'path': [{'approved': 'f',\n",
      "            'canonicalSMILES': 'CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3C(NC1=O)O',\n",
      "            'comment': '7-hydroxystaurosporine is a cell-permeable <Ligand '\n",
      "                       'id=346/> derivative, with anticancer activity '\n",
      "                       '<Reference id=26172/>. It reversibly and '\n",
      "                       'ATP-competitively inhibits multiple protein kinases, '\n",
      "                       'including PKC&alpha;, &beta;, &gamma;, &delta; and '\n",
      "                       '&epsilon; <Reference id=26176/>, Chk1 <Reference '\n",
      "                       'id=26175/><Reference id=25819/><Reference id=26173/>, '\n",
      "                       'Cdc25C-associated protein kinase 1 (cTAK1) <Reference '\n",
      "                       'id=26175/>, Cdk1 <Reference id=25819/>, PAK4, '\n",
      "                       'Cdk5/p25, Chk2 <Reference id=26175/>, PDK1 <Reference '\n",
      "                       'id=26174/>, Lck <Reference id=25819/>, p38 MAPK kinase '\n",
      "                       '2 (MAPK14) <Reference id=26173/>, Akt, GSK-3&beta; '\n",
      "                       '<Reference id=25819/> and PKA <Reference id=26172/>.',\n",
      "            'inChI': 'InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1',\n",
      "            'inChIKey': 'PBCZSGKMGDDXIJ-HQCWYSJUSA-N',\n",
      "            'isomericSMILES': 'CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@H](NC1=O)O',\n",
      "            'label': '7-hydroxystaurosporine',\n",
      "            'ligandName': '7-hydroxystaurosporine',\n",
      "            'synonym': 'UCN 01',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/ligand7907'},\n",
      "           'hasLigand',\n",
      "           {'uri': 'https://rdf.guidetopharmacology.org/GRAC/interaction80783'},\n",
      "           'hasTarget',\n",
      "           {'label': 'protein kinase A',\n",
      "            'nomenclature': 'protein kinase A',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/target1694'},\n",
      "           'hasTargetFamily',\n",
      "           {'label': 'Protein kinase A (PKA) family',\n",
      "            'targetFamilyName': 'Protein kinase A (PKA) family',\n",
      "            'uri': 'https://rdf.guidetopharmacology.org/GRAC/targetFamily284'}],\n",
      "  'r': {'uri': 'http://identifiers.org/pubmed/15486189'}}]\n"
     ]
    }
   ],
   "source": [
    "from pprint import pprint\n",
    "\n",
    "pprint(results)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "cypher_query = \"\"\"\n",
    "MATCH (l:Resource)\n",
    "WHERE l.ligandName IN ['5-nitroso-8-quinolinol', '7-hydroxystaurosporine', 'alisertib', 'AMG 900', 'AR-42',\n",
    "    'AT7519', 'AZD1152-HQPA', 'AZD5438', 'belinostat', 'Bms-265246', 'CCT129202', 'CCT137690',\n",
    "    'CYC116', 'dinaciclib', 'ENMD-2076', 'entinostat', 'flavopiridol', 'indisulam', 'M 344',\n",
    "    'nexturastat A', 'panobinostat', 'PF-03814735', 'PHA-793887', 'pyroxamide', 'R-547',\n",
    "    'R306465', 'resminostat', 'RGFP966', 'ricolinostat', 'riviciclib', 'SB1317/TG02', 'Sns-032',\n",
    "    'SNS-314 mesylate', 'tozasertib', 'ZM-447439']\n",
    "MATCH path = (l)-[:hasLigand]-(i)-[:hasTarget]-(t)-[:hasTargetFamily]-(tf)\n",
    "    OPTIONAL MATCH (i)-[:hasAction]-(a)\n",
    "    OPTIONAL MATCH (i)-[:hasAffinity]-(af)\n",
    "    OPTIONAL MATCH (i)-[:hasReference]-(r)\n",
    "    OPTIONAL MATCH (l)-[:xref]-(xr)\n",
    "RETURN \n",
    "    l.label as Compound,\n",
    "    l.approved as FDA_Approved,\n",
    "    t.label as Target,\n",
    "    tf.label as Target_Family,\n",
    "    a.uri as Action,\n",
    "    af.hasMedianValue as Affinity,\n",
    "    af.hasLowValue as Affinity_Low,\n",
    "    af.hasHighValue as Affinity_High,\n",
    "    r.uri as Reference,\n",
    "    l.comment as Description,\n",
    "    l.inChIKey as InChIKey,\n",
    "    l.canonicalSMILES as SMILES,\n",
    "    xr.uri as CHEMBL\n",
    "ORDER BY l.ligandName, t.nomenclature\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# Execute the query and display the results\n",
    "results = run_cypher_query(cypher_query)\n",
    "\n",
    "df = pd.DataFrame(results)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Compound</th>\n",
       "      <th>FDA_Approved</th>\n",
       "      <th>Target</th>\n",
       "      <th>Target_Family</th>\n",
       "      <th>Action</th>\n",
       "      <th>Affinity</th>\n",
       "      <th>Affinity_Low</th>\n",
       "      <th>Affinity_High</th>\n",
       "      <th>Reference</th>\n",
       "      <th>Description</th>\n",
       "      <th>InChIKey</th>\n",
       "      <th>SMILES</th>\n",
       "      <th>CHEMBL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>7-hydroxystaurosporine</td>\n",
       "      <td>f</td>\n",
       "      <td>3-phosphoinositide dependent protein kinase 1</td>\n",
       "      <td>PDK1 family</td>\n",
       "      <td>https://rdf.guidetopharmacology.org/ns/gtpo#In...</td>\n",
       "      <td>7.48</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>http://identifiers.org/pubmed/11896604</td>\n",
       "      <td>7-hydroxystaurosporine is a cell-permeable &lt;Li...</td>\n",
       "      <td>PBCZSGKMGDDXIJ-HQCWYSJUSA-N</td>\n",
       "      <td>CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1...</td>\n",
       "      <td>http://identifiers.org/chembl.compound/CHEMBL1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>7-hydroxystaurosporine</td>\n",
       "      <td>f</td>\n",
       "      <td>LCK proto-oncogene, Src family tyrosine kinase</td>\n",
       "      <td>Src family</td>\n",
       "      <td>https://rdf.guidetopharmacology.org/ns/gtpo#In...</td>\n",
       "      <td>7.30</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>http://identifiers.org/pubmed/15486189</td>\n",
       "      <td>7-hydroxystaurosporine is a cell-permeable &lt;Li...</td>\n",
       "      <td>PBCZSGKMGDDXIJ-HQCWYSJUSA-N</td>\n",
       "      <td>CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1...</td>\n",
       "      <td>http://identifiers.org/chembl.compound/CHEMBL1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>7-hydroxystaurosporine</td>\n",
       "      <td>f</td>\n",
       "      <td>checkpoint kinase 1</td>\n",
       "      <td>CHK1 subfamily</td>\n",
       "      <td>https://rdf.guidetopharmacology.org/ns/gtpo#In...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7.46</td>\n",
       "      <td>8.15</td>\n",
       "      <td>http://identifiers.org/pubmed/10786669</td>\n",
       "      <td>7-hydroxystaurosporine is a cell-permeable &lt;Li...</td>\n",
       "      <td>PBCZSGKMGDDXIJ-HQCWYSJUSA-N</td>\n",
       "      <td>CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1...</td>\n",
       "      <td>http://identifiers.org/chembl.compound/CHEMBL1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>7-hydroxystaurosporine</td>\n",
       "      <td>f</td>\n",
       "      <td>checkpoint kinase 1</td>\n",
       "      <td>CHK1 subfamily</td>\n",
       "      <td>https://rdf.guidetopharmacology.org/ns/gtpo#In...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7.46</td>\n",
       "      <td>8.15</td>\n",
       "      <td>http://identifiers.org/pubmed/15486189</td>\n",
       "      <td>7-hydroxystaurosporine is a cell-permeable &lt;Li...</td>\n",
       "      <td>PBCZSGKMGDDXIJ-HQCWYSJUSA-N</td>\n",
       "      <td>CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1...</td>\n",
       "      <td>http://identifiers.org/chembl.compound/CHEMBL1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>7-hydroxystaurosporine</td>\n",
       "      <td>f</td>\n",
       "      <td>checkpoint kinase 1</td>\n",
       "      <td>CHK1 subfamily</td>\n",
       "      <td>https://rdf.guidetopharmacology.org/ns/gtpo#In...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>7.46</td>\n",
       "      <td>8.15</td>\n",
       "      <td>http://identifiers.org/pubmed/17292828</td>\n",
       "      <td>7-hydroxystaurosporine is a cell-permeable &lt;Li...</td>\n",
       "      <td>PBCZSGKMGDDXIJ-HQCWYSJUSA-N</td>\n",
       "      <td>CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1...</td>\n",
       "      <td>http://identifiers.org/chembl.compound/CHEMBL1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>riviciclib</td>\n",
       "      <td>f</td>\n",
       "      <td>cyclin dependent kinase 9</td>\n",
       "      <td>CDK9 subfamily</td>\n",
       "      <td>https://rdf.guidetopharmacology.org/ns/gtpo#In...</td>\n",
       "      <td>7.70</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>http://identifiers.org/pubmed/17363486</td>\n",
       "      <td>Riviciclib is a flavone based cyclin dependent...</td>\n",
       "      <td>QLUYMIVVAYRECT-OCCSQVGLSA-N</td>\n",
       "      <td>OCC1N(C)CCC1c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>tozasertib</td>\n",
       "      <td>f</td>\n",
       "      <td>aurora kinase A</td>\n",
       "      <td>Aurora kinase (Aur) family</td>\n",
       "      <td>https://rdf.guidetopharmacology.org/ns/gtpo#In...</td>\n",
       "      <td>8.41</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>http://identifiers.org/pubmed/22037378</td>\n",
       "      <td>Tozasertib is a potent inhibitor of all three ...</td>\n",
       "      <td>GCIKSSRWRFVXBI-UHFFFAOYSA-N</td>\n",
       "      <td>CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)N...</td>\n",
       "      <td>http://identifiers.org/chembl.compound/CHEMBL5...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>tozasertib</td>\n",
       "      <td>f</td>\n",
       "      <td>aurora kinase A</td>\n",
       "      <td>Aurora kinase (Aur) family</td>\n",
       "      <td>https://rdf.guidetopharmacology.org/ns/gtpo#In...</td>\n",
       "      <td>9.22</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>http://identifiers.org/pubmed/14981513</td>\n",
       "      <td>Tozasertib is a potent inhibitor of all three ...</td>\n",
       "      <td>GCIKSSRWRFVXBI-UHFFFAOYSA-N</td>\n",
       "      <td>CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)N...</td>\n",
       "      <td>http://identifiers.org/chembl.compound/CHEMBL5...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>tozasertib</td>\n",
       "      <td>f</td>\n",
       "      <td>aurora kinase B</td>\n",
       "      <td>Aurora kinase (Aur) family</td>\n",
       "      <td>https://rdf.guidetopharmacology.org/ns/gtpo#In...</td>\n",
       "      <td>7.74</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>http://identifiers.org/pubmed/14981513</td>\n",
       "      <td>Tozasertib is a potent inhibitor of all three ...</td>\n",
       "      <td>GCIKSSRWRFVXBI-UHFFFAOYSA-N</td>\n",
       "      <td>CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)N...</td>\n",
       "      <td>http://identifiers.org/chembl.compound/CHEMBL5...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>tozasertib</td>\n",
       "      <td>f</td>\n",
       "      <td>aurora kinase C</td>\n",
       "      <td>Aurora kinase (Aur) family</td>\n",
       "      <td>https://rdf.guidetopharmacology.org/ns/gtpo#In...</td>\n",
       "      <td>8.34</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>http://identifiers.org/pubmed/14981513</td>\n",
       "      <td>Tozasertib is a potent inhibitor of all three ...</td>\n",
       "      <td>GCIKSSRWRFVXBI-UHFFFAOYSA-N</td>\n",
       "      <td>CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)N...</td>\n",
       "      <td>http://identifiers.org/chembl.compound/CHEMBL5...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>93 rows  13 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                  Compound FDA_Approved  \\\n",
       "0   7-hydroxystaurosporine            f   \n",
       "1   7-hydroxystaurosporine            f   \n",
       "2   7-hydroxystaurosporine            f   \n",
       "3   7-hydroxystaurosporine            f   \n",
       "4   7-hydroxystaurosporine            f   \n",
       "..                     ...          ...   \n",
       "88              riviciclib            f   \n",
       "89              tozasertib            f   \n",
       "90              tozasertib            f   \n",
       "91              tozasertib            f   \n",
       "92              tozasertib            f   \n",
       "\n",
       "                                            Target  \\\n",
       "0    3-phosphoinositide dependent protein kinase 1   \n",
       "1   LCK proto-oncogene, Src family tyrosine kinase   \n",
       "2                              checkpoint kinase 1   \n",
       "3                              checkpoint kinase 1   \n",
       "4                              checkpoint kinase 1   \n",
       "..                                             ...   \n",
       "88                       cyclin dependent kinase 9   \n",
       "89                                 aurora kinase A   \n",
       "90                                 aurora kinase A   \n",
       "91                                 aurora kinase B   \n",
       "92                                 aurora kinase C   \n",
       "\n",
       "                 Target_Family  \\\n",
       "0                  PDK1 family   \n",
       "1                   Src family   \n",
       "2               CHK1 subfamily   \n",
       "3               CHK1 subfamily   \n",
       "4               CHK1 subfamily   \n",
       "..                         ...   \n",
       "88              CDK9 subfamily   \n",
       "89  Aurora kinase (Aur) family   \n",
       "90  Aurora kinase (Aur) family   \n",
       "91  Aurora kinase (Aur) family   \n",
       "92  Aurora kinase (Aur) family   \n",
       "\n",
       "                                               Action  Affinity  Affinity_Low  \\\n",
       "0   https://rdf.guidetopharmacology.org/ns/gtpo#In...      7.48           NaN   \n",
       "1   https://rdf.guidetopharmacology.org/ns/gtpo#In...      7.30           NaN   \n",
       "2   https://rdf.guidetopharmacology.org/ns/gtpo#In...       NaN          7.46   \n",
       "3   https://rdf.guidetopharmacology.org/ns/gtpo#In...       NaN          7.46   \n",
       "4   https://rdf.guidetopharmacology.org/ns/gtpo#In...       NaN          7.46   \n",
       "..                                                ...       ...           ...   \n",
       "88  https://rdf.guidetopharmacology.org/ns/gtpo#In...      7.70           NaN   \n",
       "89  https://rdf.guidetopharmacology.org/ns/gtpo#In...      8.41           NaN   \n",
       "90  https://rdf.guidetopharmacology.org/ns/gtpo#In...      9.22           NaN   \n",
       "91  https://rdf.guidetopharmacology.org/ns/gtpo#In...      7.74           NaN   \n",
       "92  https://rdf.guidetopharmacology.org/ns/gtpo#In...      8.34           NaN   \n",
       "\n",
       "    Affinity_High                               Reference  \\\n",
       "0             NaN  http://identifiers.org/pubmed/11896604   \n",
       "1             NaN  http://identifiers.org/pubmed/15486189   \n",
       "2            8.15  http://identifiers.org/pubmed/10786669   \n",
       "3            8.15  http://identifiers.org/pubmed/15486189   \n",
       "4            8.15  http://identifiers.org/pubmed/17292828   \n",
       "..            ...                                     ...   \n",
       "88            NaN  http://identifiers.org/pubmed/17363486   \n",
       "89            NaN  http://identifiers.org/pubmed/22037378   \n",
       "90            NaN  http://identifiers.org/pubmed/14981513   \n",
       "91            NaN  http://identifiers.org/pubmed/14981513   \n",
       "92            NaN  http://identifiers.org/pubmed/14981513   \n",
       "\n",
       "                                          Description  \\\n",
       "0   7-hydroxystaurosporine is a cell-permeable <Li...   \n",
       "1   7-hydroxystaurosporine is a cell-permeable <Li...   \n",
       "2   7-hydroxystaurosporine is a cell-permeable <Li...   \n",
       "3   7-hydroxystaurosporine is a cell-permeable <Li...   \n",
       "4   7-hydroxystaurosporine is a cell-permeable <Li...   \n",
       "..                                                ...   \n",
       "88  Riviciclib is a flavone based cyclin dependent...   \n",
       "89  Tozasertib is a potent inhibitor of all three ...   \n",
       "90  Tozasertib is a potent inhibitor of all three ...   \n",
       "91  Tozasertib is a potent inhibitor of all three ...   \n",
       "92  Tozasertib is a potent inhibitor of all three ...   \n",
       "\n",
       "                       InChIKey  \\\n",
       "0   PBCZSGKMGDDXIJ-HQCWYSJUSA-N   \n",
       "1   PBCZSGKMGDDXIJ-HQCWYSJUSA-N   \n",
       "2   PBCZSGKMGDDXIJ-HQCWYSJUSA-N   \n",
       "3   PBCZSGKMGDDXIJ-HQCWYSJUSA-N   \n",
       "4   PBCZSGKMGDDXIJ-HQCWYSJUSA-N   \n",
       "..                          ...   \n",
       "88  QLUYMIVVAYRECT-OCCSQVGLSA-N   \n",
       "89  GCIKSSRWRFVXBI-UHFFFAOYSA-N   \n",
       "90  GCIKSSRWRFVXBI-UHFFFAOYSA-N   \n",
       "91  GCIKSSRWRFVXBI-UHFFFAOYSA-N   \n",
       "92  GCIKSSRWRFVXBI-UHFFFAOYSA-N   \n",
       "\n",
       "                                               SMILES  \\\n",
       "0   CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1...   \n",
       "1   CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1...   \n",
       "2   CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1...   \n",
       "3   CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1...   \n",
       "4   CNC1CC2OC(C1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1...   \n",
       "..                                                ...   \n",
       "88     OCC1N(C)CCC1c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O   \n",
       "89  CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)N...   \n",
       "90  CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)N...   \n",
       "91  CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)N...   \n",
       "92  CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)N...   \n",
       "\n",
       "                                               CHEMBL  \n",
       "0   http://identifiers.org/chembl.compound/CHEMBL1...  \n",
       "1   http://identifiers.org/chembl.compound/CHEMBL1...  \n",
       "2   http://identifiers.org/chembl.compound/CHEMBL1...  \n",
       "3   http://identifiers.org/chembl.compound/CHEMBL1...  \n",
       "4   http://identifiers.org/chembl.compound/CHEMBL1...  \n",
       "..                                                ...  \n",
       "88                                               None  \n",
       "89  http://identifiers.org/chembl.compound/CHEMBL5...  \n",
       "90  http://identifiers.org/chembl.compound/CHEMBL5...  \n",
       "91  http://identifiers.org/chembl.compound/CHEMBL5...  \n",
       "92  http://identifiers.org/chembl.compound/CHEMBL5...  \n",
       "\n",
       "[93 rows x 13 columns]"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": [
    "# export the DataFrame to a xlsx file\n",
    "df.to_excel('ligand_target_data.xlsx', index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "driver.close()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### NOTES:  additional tools"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Nulling out a Neo4j database"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "# uncomment and use only when required - a quick way to clear the database\n",
    "\n",
    "# cypher_query = \"\"\"\n",
    "# MATCH (n) DETACH DELETE n\n",
    "# \"\"\"\n",
    "\n",
    "# results = run_cypher_query(cypher_query)\n",
    "# driver.close()\n",
    "\n",
    "# pprint(results)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "YRjw24yMavka"
   },
   "source": [
    "## Citation\n",
    "\n",
    "**BibTeX:**\n",
    "\n",
    "```\n",
    "@article{10.1093/nar/gkad944,\n",
    "    author = {Harding, Simon D and Armstrong, Jane F and Faccenda, Elena and Southan, Christopher and Alexander, StephenP H and Davenport, Anthony P and Spedding, Michael and Davies, Jamie A},\n",
    "    title = \"{The IUPHAR/BPS Guide to PHARMACOLOGY in 2024}\",\n",
    "    journal = {Nucleic Acids Research},\n",
    "    volume = {52},\n",
    "    number = {D1},\n",
    "    pages = {D1438-D1449},\n",
    "    year = {2023},\n",
    "    month = {10},\n",
    "    abstract = \"{The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb; https://www.guidetopharmacology.org) is an open-access, expert-curated, online database that provides succinct overviews and key references for pharmacological targets and their recommended experimental ligands. It includes over 3039 protein targets and 12163 ligand molecules, including approved drugs, small molecules, peptidesand antibodies. Here, we report recent developments to the resource and describe expansion in content over the six database releases made during the last two years. The database update section of this paper focuses on two areas relating to important global health challenges. The first, SARS-CoV-2 COVID-19, remains a major concern and we describe our efforts to expand the database to include a new family of coronavirus proteins. The second area is antimicrobial resistance, for which we have extended our coverage of antibacterials in partnership with AntibioticDB, a collaboration that has continued through support from GARDP. We discuss other areas of curation and also focus on our external links to resources such as PubChem that bring important synergies to the resources.}\",\n",
    "    issn = {0305-1048},\n",
    "    doi = {10.1093/nar/gkad944},\n",
    "    url = {https://doi.org/10.1093/nar/gkad944},\n",
    "    eprint = {https://academic.oup.com/nar/article-pdf/52/D1/D1438/55039511/gkad944.pdf},\n",
    "}\n",
    "```"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "kRtn41uiaxuE"
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "colab": {
   "name": "gtpd_init.ipynb",
   "provenance": []
  },
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
